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MAPPING THE HUMAN VASCULATURE BY IN VIVO PHAGE DISPLAY

Julianna Kim Bronk, B.S.
Advisory Professor: George Calin, M.D., Ph.D.

In vivo phage display screenings by intravenous injection of a random phage-displayed
peptide library allow for the selection of peptides that localize to specific vascular beds.
At the University of Texas MD Anderson Cancer Center, we have had the opportunity to
perform phage display screenings in cancer patients in order to select for cancer specific
targets directly in humans. These targets serve to define biochemical diversity of
endothelial cell surfaces and can be validated and explored towards the design of
vascular-targeted pharmacology. In the most recent patient screen, samples were
recovered from hepatocellular carcinoma (HCC) as well as 26 additional tissues. Highthroughput sequencing and multidimensional bioinformatics analysis of recovered
peptides led to the identification of extensive panels of motifs that are predicted to
distinctly localize to tissue-specific vascular beds. Utilizing peptide affinity purification
and phage based binding assays, we have shown that the HCC targeting peptide
(SGVGAASL) identified from this patient screen, selectively binds to HCC in vitro as
well as in vivo facilitated by a receptor mediated interaction with the giantin protein.
FACS and protein fractionational experiments showed that the giantin polypeptide,
normally considered an intracellular protein, is uniquely expressed on the surface of HCC
cell lines as well as activated endothelial cells. shRNA mediated depletion of giantin
expression lead to a loss of proliferation and adhesion in cancer cells. Finally, an
extensive study of giantin expression in patient HCC tissue uncovered a unique
vi

expression pattern on the surface of tumor-associated vasculature. Collectively, these data
support a functional role for giantin on the surface of HCC tumor endothelium that could
potentially be exploited for delivery of imaging and therapeutic agents. Ultimately, this
work serves as the foundation of a high-throughput integrative platform for discovery and
validation of tissue-specific motifs towards a comprehensive understanding of the
vascular landscape in humans.
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CHAPTER 1: INTRODUCTION AND REVIEW OF THE LITERATURE

1.1

Overview of the vascular system
During vertebrate development, the cardiovascular system is the first organ

system to be formed and reach a functional state. The vascular system makes up an
intricate network that connects each of the organ systems of the body with the vital
purposes of transporting oxygen and nutrients to tissues and exporting waste from tissues
[1]. Vessels are composed of an inner lining or endothelium made up of endothelial cells
that arrange into an epithelial layer that surrounds the internal lumen of the vessel. In
small vessels, the endothelium consists of vascular smooth cells and pericytes whereas in
large arteries and veins, smooth muscle cells, connective tissue, collagen and elastic
fibers form the support structure [1-3]. This structure allows vessels to dynamically adapt
to changing demands for nutrients and oxygen throughout the body. In extreme cases of
chronic changes, the remodeling of vascular beds may be required to restore homeostasis.

1.1.1

Endothelial cell heterogeneity

Phenotypic heterogeneity across the so called “vascular tree” is the core property
of the vascular system. Variations in structural as well as molecular properties in the
endothelium play a critical role in many physiological functions including vasomotor
tone, leukocyte trafficking, hemostasis, permeability, angiogenesis, and immunity [4].
Phenotypic endothelial cell heterogeneity provides the endothelium with the ability to
meet the varied needs of tissues throughout the body. For example, under conditions of
acute or chronic inflammation, endothelial cells are able to induce permeability by
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regulation of cell junctions as well as allow for site specific receptor mediated
transcytosis [4, 5]. Traditionally, identification of various endothelial cell phenotypes has
been performed using, immunohistochemistry, in situ hybridization, intravital
microscopy, and proteomic techniques such as antibody and phage screenings [5-7].

1.1.2

Angiogenesis

Angiogenesis, the formation of new vessels from existing vasculature, occurs
during embryonic development to establish the foundation of the vascular system for
growing and developing organs [8]. In adults, angiogenesis is involved in physiological
repair processes such as wound healing and occurs in a highly ordered, tightly regulated
fashion [9]. Under normal conditions, angiogenesis induces quiescent endothelial cells to
extend the vascular network only to the extent that meets the demands of growing tissue.
This process requires a coordinated signaling network of various mediators including
soluble growth factors (vascular endothelial growth factor (VEGF), fibroblast growth
factor, platelet-derived growth factor, and transforming growth factor-β) and membranebound molecules enabling cell-cell interactions (αvβ3-integrin, VE-cadherin, and ephB4/ephrin-B2) [8].
In order to satisfy the metabolic demands for proliferation and survival, tumor
cells, host-derived cells that have lost the ability to regulate growth, retain characteristics
that are similar to non-transformed cells including the need for a supply of oxygen,
delivery of nutrients, and removal of waste. Initially, tumors can grow around established
vasculature in order to meet their metabolic needs. Tumor-induced angiogenesis occurs
when the existing vasculature is inadequate to sustain tumor survival and it must establish
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its own blood supply through neovascularization [10, 11]. Exploiting angiogenesis to
promote disease has several key advantages. First, it allows for the critical transport of
oxygen, nutrients, and waste to and from the disease site. Second, newly developed blood
vessels share host immunity, therefore, allowing the tumor to evade immunologic attack.
Finally, conditions in the tumor create a proliferative phenotype in endothelial cells that
are normally quiescent allowing for continuous growth of vessels to support the tumor [8,
12, 13]. Although the formation of tumor-associated vasculature is made possible by
commandeering host angiogenic mechanisms, the vessels themselves are structurally
abnormal. These abnormalities include distended and convoluted vessels, a lack of
functional pericytes, and general “leakiness” due to fenestrae or holes in the incomplete
basement membrane [8]. Interestingly, tumor vasculature may contain both endothelial
cells and tumor cells (“mosaic” tumor vessels) [14].

1.1.3

Anti-angiogenic therapy

Physiological and pathological inhibitors of angiogenesis have been explored in
the context of cancer therapeutics. The strategy behind anti-angiogenic therapy is to
develop an agent that will inhibit blood vessel growth, thus, suppressing the ability of the
tumor to proliferate and survive. Many angiogenesis inhibitors are already undergoing
clinical trials [8]. For example, in 2004, bevacizumab (Avastin), a monoclonal antibody
targeting VEGF-A developed by Genentech/Roche, was the first targeted antiangiogenesis cancer therapy to be approved by the Food and Drug Administration (FDA)
and has since become the most widely prescribed anti-angiogenic therapy in various
types of cancer [15]. However, many targeted anti-angiogenic therapies are limited by
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drug resistance, side effects, and toxicity including a risk of hypertension, gastrointestinal
disorders, and hemorrhaging [16]. In particular, recent studies have shown evidence of
increased aggression in tumor recurrence following the withdrawal of anti-angiogenic
therapy likely due to the selective pressures promoting tumor invasion and metastasis
such as a hypoxic microenvironment and survival of resistant cell subpopulations [17].
Interestingly, an endogenous angiogenesis inhibitor, endostatin, a 20 kDa protein derived
from the proteolytic cleavage of collagen XVIII, has been shown to inhibit endothelial
cell proliferation, angiogenesis, and tumor growth in mice and no resistance has been
observed in humans [18, 19]. Unfortunately, during clinical trials, no significant
improvements in tumor response or progression were observed in patients treated with
endostatin alone. Subsequent studies have shown that endostatin may be beneficial in
combination with other therapies [20]. Additional strategies to develop anti-angiogenic
agents as a form of cancer vaccine to prevent tumor development at early stages are also
underway [8]. Despite the current shortcomings in anti-angiogenic therapy, there remain
many avenues for improvement and optimization towards the improvement of clinical
cancer care.

1.2

Bacteriophage
Phage display was first described by George Smith as a technique to identify

antibody binding sites. In this seminal study, filamentous bacteriophage (phage), a single
stranded DNA virus that infect gram-negative bacteria, were genetically engineered to
express or “display” a short protein sequence taken from the EcoRI endonuclease gene on
the outer phage capsid protein III (pIII) (Fig. 1-1) [21]. These modified “fusion phage”
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Fig. 1-1. General filamentous
ilamentous phage structure. a) Schematic of bacteriophage coat
protein structure and arrangement
arrangement.. b) Individual representation of bacteriophage coat
proteins, molecular weight, size and copy number per virion. Reprinted with permission
from Løset GÅ, Roos N, Bogen B, Sandlie I. Expanding the Versatility of Phage Display
II: Improved Affinity Selectio
Selection
n of Folded Domains on Protein VII and IX of the
Filamentous Phage. PLoS ONE. 2011. 6(2): e17433. Copyright: © 2011 Løset et al. This
is an open-access
access article distributed under the terms of the Creative Commons Attribution
License, which permits unrestric
unrestricted
ted use, distribution, and reproduction in any medium,
provided the original author and source are credited.
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particles retained their ability to infect and replicate in bacteria, and after panning for
affinity to an antibody against EcoRI, they were found to be enriched over normal wild
type phage. This technique has since been widely explored and expanded for various
applications aimed at discovering and understanding important protein-protein
interactions. Phage-displayed peptide libraries have been constructed with a diversity of
greater than 109 different clones per library displaying random peptides on the pIII capsid
that vary in length and contain frequent cysteine residues thereby creating conformational
“loops” in the sequence displayed [22]. These combinatorial libraries have proven to be
tremendously advantageous for the development of screening methodologies used to
isolate peptide ligands.

1.2.1

Phage display screening for molecular targets in cells

Phage display has been used as a methodology to perform systemic profiling of
protein expression for clinically relevant markers in various settings including circulating
antibodies, recombinant proteins and isolated protein extracts, and cell lines [23-30].
Phage libraries were used to investigate tumor specific antibodies found in the serum of
prostate cancer patients, leading to the identification of a cyclic peptide that selectively
bound to tumor-associated antibodies over control antibodies from blood donors [23].
This study was extended to show that the identified peptide mimicked a region of the
tumor antigen, glucose regulated protein-78 (GRP78), known to be overexpressed in
cancer. Further identification and examination of GRP78 binding motifs in preclinical
prostate cancer models demonstrated that GRP78 is a strong candidate for targeted
therapy in metastatic prostate cancer [25]. In a similar study in ovarian cancer, antibody
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fingerprinting by phage display combinatorial selection was performed to identify tumorrelated antibodies present in ascities fluid in patients with advanced disease [24]. A
consensus motif was isolated from this screen and was found to mimic heat-shock
protein-90 (HSP-90). In a large panel of ovarian cancer patients, HSP-90 expression was
found to be elevated; however, humoral response was restricted to patients with stage IV
disease.
Likewise, phage display technology has also been directly applied towards
elucidating the details of protein-protein interactions with the goal to identify potential
small ligand inhibitors of cancer and other diseases. In a study involving DNA repair, a
screen performed on cell nuclear extract prepared from irradiated cells uncovered a
ligand binding to and inactivating DNA-dependent protein kinase involved in DNA
double-strand break repair. This inactivating ligand was also found to sensitize BRCAdeficient cancer cells to genotoxic therapy [26]. This approach takes advantage of
synthetic lethality where inhibition of a DNA-repair pathway target as well as the
presence of a mutation due to selective pressures during tumor evolution may sensitize
tumor cells while having no effect on healthy cells. Similarly, in a study to uncover
binding mechanisms of Staphylococcus aureus (S. aureus) mediated through microbial
surface components recognizing adhesive matrix molecules, a phage panning directly on
recombinant SdrC, natively expressed in S. aureus, uncovered a novel interaction
mediating bacterial colonization in host tissues [27]. Knowledge of this interaction could
potentially lead to the design and development of antimicrobial therapies.
In 2001, Giordano et al. developed a methodology for probing the cell surface in
vitro using combinatorial phage-displayed libraries by organic phase separation [28]. The
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initial characterization of this protocol was implemented to identify peptide ligands
binding to the VEGF receptor (VEGFR) expressed on the surface of endothelial cells and
has since been extended to numerous cell lines. For example, Kolonin et al., performed a
phage-displayed random peptide library screen in a panel of 60 cell lines derived from
human tumors (NCI-60) [29]. Just as gene arrays have been used to identify similarities
and differences between tumor types, the diversity of peptides recovered allowed for
profiling of cell surface markers present in each cell line. By classifying cell lines by
recovered tri-peptide motifs, Kolonin et al. were able to identify domains of human
proteins that serve as ligands to receptors in tumor cells and classify the cell lines in the
NCI-60 panel by expression profiles of their corresponding tumor receptors. Several
peptide motifs mimicking native ligands of the epidermal growth factor receptor were
validated for binding specificity and targeting ability in these studies [29, 30].

1.2.2

In vivo phage display for proteomic profiling of blood vessels

In vitro methods for protein profiling do not take into account the physiological
context of protein-protein interactions. In particular, interactions occurring in specific
vascular beds that are accessible by therapeutic agents traveling in the bloodstream
represent ideal candidates for targeted delivery applications [5, 31]. Furthermore,
angiogenic vessels have been known to express receptors or other molecules that are not
present in normal blood vessels [6]. Attempts to isolate endothelial cells ex vivo by
freshly harvesting them from animals are problematic because once removed from their
native environment, these cells may undergo phenotypic drift introducing artifacts into
subsequent findings [32, 33]. For example, in a study by Durr et al., over 40% of proteins
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expressed on the plasma membrane of rat lung microvascular endothelial cells were not
detected in vitro after cells were harvested and cultured [33]. Study of vascular
proteomics in vivo has been explored by several groups beginning with the identification
of peptides homing to normal and tumor blood vessels (Fig. 1-2a) [34, 35]. Since this
initial work, phage-displayed peptide libraries have been used to screen for molecular
targets using various preclinical models including disease of the lymph node, brain,
prostate, breast, and fat tissue [36-40].
Accessible proteins in the vasculature of diseased tissues have the potential to
serve as excellent targets for therapy strategies (Fig 1-2b). This specificity not only
allows for increased therapeutic effects but also may minimize damage to healthy cells.
Furthermore, previous drug candidates of limited effectiveness may gain efficacy when
directly targeted to a disease site. The use of in vivo models for phage display is
immensely beneficial because it grants the ability to uncover targets under native
conditions. Furthermore, several of these screens have indicated that the selected tissue
specific peptides often mimic biological ligands that can be important for disease
establishment and progression. In these cases, the peptides themselves may exhibit
therapeutic properties by interfering with interactions required for disease persistence
[41, 42].
Despite the utility of preclinical models, experiments performed in artificial
settings must be carefully validated before being extrapolated to human applications.
Direct selection of phage libraries in a patient was first reported by Arap et al. in 2002
[31]. In this large-scale screening, 47,160 tri-peptide motifs were identified to localize to
normal or tumor-associated vasculature and the tissue distribution of these peptides was
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Fig. 1-2.
2. In vivo phage display. a) Peptide ligands displayed on phage can home to
receptors expressed on the surface of tissue endothelium. b) These peptide ligands can be
used for directing therapy to specific tissues and organs. Reprinted with permission from
Kolonin M, Pasqualini R, Arap W. Molecular addresses in blood vessels as targets for
therapy. Curr Opin Chem Biol. 2001 Jun;5(3):308
Jun;5(3):308-13.
13. Copyright: © 2001 Elsevier
Science Ltd.
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determined to be nonrandom. This work led to the generation of a targeted drug for
patients with metastatic prostate cancer. A peptide found to mimic interleukin 11 and
bind to the interleukin 11 receptor alpha which is upregulated on the surface of bonemarrow metastasis was conjugated to a pro-apoptotic moiety (D[KLAKLAK]2). This
formulation, called bone-marrow targeting peptide 11, has since been shown to be
therapeutically active in several types of cancer including prostate cancer metastasis to
bone, osteosarcoma, and osteosarcoma metastasis to lung [43, 44] as well as non-small
cell lung cancer (NSCLC) and leukemia (data in preparation). Subsequent screenings in
patients have been performed with the overarching goal of mapping human vasculature
heterogeneity towards the development of molecularly targeted drugs and imaging
agents.

1.2.3

Next-generation phage display

Recent advances in sequencing capabilities have revolutionized the field of
genomics; however, it is widely accepted that DNA sequence alone is not sufficient to
fully describe how proteins function and interact in their environment. The combination
of high-throughput sequencing and combinatorial phage display has been applied towards
building a more complete understanding of protein function and protein-protein
interactions. In either an in vitro or in vivo phage display screen, the two rate-limiting
steps include quantifying phage homing (traditionally performed by allowing particles to
infect bacteria and confer resistance, selecting for infected bacteria by plating on agar
containing antibiotics, and counting colonies the following day) as well as identification
of the amino acid sequence of the peptide displayed on each phage by DNA sequencing

11

of individual bacterial colonies. To address these limitations, Dias-Neto et al. [45]
eliminated the reliance on host bacteria and utilized real-time PCR for rapid phage
quantification and high-throughput sequencing for large-scale analysis of phage display
screening data. By implementing these improvements, they were able to perform phage
display screenings 1,000 x faster and 250 x cheaper while recovering over 100 x more
sequences. For example, high-throughput sequencing enabled recovery of over 1 million
peptide inserts per run whereas traditional Sanger sequencing was limited to the number
of bacterial colonies manually tested. Furthermore, the analyzed sequence dataset
included over 90% of the phage diversity present in each targeted tissue suggesting that
the diversity in these tissues was covered (Fig 1-3). By leveraging this exponential
increase in recovered data from a single screen, a panel of novel protein-protein
interactions were identified in a patient screen and four were further validated and
characterized in the context of normal and disease tissues [46].
Following the development of next-generation technologies for large-scale phage
screenings, several other groups have utilized this technology for high-throughput phage
display applications. Di Niro et al. have developed and characterized a cDNA phage
library displaying open reading frames of the human genome [47]. They identified
several known as well as novel protein-protein interactions involving the
transglutaminase 2 enzyme interaction network by large scale recovery of phage
sequences. Likewise, Fowler et al. have developed a high-throughput approach for
investigating sequence variation in the context of ligand binding towards optimized drug
development [48]. By performing multiple rounds of selection coupled with deep-
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Fig. 1-3.
3. Saturation plots of peptide diversity coverage after next
next-generation
generation
sequencing. The number of distinct pep
peptides
tides observed in bone marrow (a), fat (b),
muscle (c), skin (d) or the non
non-selected
selected library (e), are shown as a function of the total
number of peptide sequences evaluated for each tissue. Adapted from Dias
Dias-Neto
Neto E,
Nunes DN, Giordano RJ, Sun J, Botz GH, eet al. Next-Generation
Generation Phage Display:
Integrating and Comparing Available Molecular Tools to Enable Cost
Cost-Effective
Effective HighHigh
Throughput Analysis. PLoS ONE. 2011. 4(12): e8338. Copyright: © 2009 Dias-Neto
Dias
et
al. This is an open-access
access article distributed under th
thee terms of the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are credited.
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sequencing of recovered phage, they were able to identify regions of the human WW
domain that were essential for binding to its peptide ligand.

1.3

Analysis of high-throughput peptide screenings
Diverse phage libraries yield vast sequence datasets and impose great demands

for efficient evaluation of experimental results. Contemporary amino acid–alignment and
assessment programs for high-throughput sequencing data analysis are needed to quickly
and reliably interpret consensus motifs from the phage sequences recovered in screenings
to facilitate the discovery of protein partners and reveal new tissue specific molecular
targets [49].
Protein sequence alignment can be performed at several different levels including
bioinformatic similarities, structural and pharmacophoric properties, and molecular
characteristics. In the early 1990s, the BLOSUM62 matrix was considered one of the
most efficient amino acid substitution matrices for sequence alignment applications. By
examining sequence similarity in related proteins, the probability of amino acid
substitution could be estimated and amino acids could be optimally grouped [50].
Drug screening tools can also be adapted for protein similarity identification
applications. Shape comparison can be more accurate than sequence-based alignments
such as BLOSUM62 when applied towards predicting molecular interactions [51, 52].
For example, the molecular alignment program ROCS (Rapid Overlay of Chemical
Structures), was developed by OpenEye Scientific Software (Sante Fe, New Mexico) as a
virtual screening tool with the capability to overlay representative volumes as a measure
of similarity between molecular shapes with mismatched volumes representing
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dissimilarity (Fig. 1-4). Furthermore, pharmacophoric characteristics are also taken into
account in the scoring algorithm. These three dimensional alignments can be valuable in
several applications including predicting protein structures and revealing binding
elements between different molecules [53].
An additional drug screening program designed by Oprea et al. in 2001 is the
chemical global positioning system (ChemGPS) or “drugspace” map developed by
applying geographical-like characteristics such as longitude and latitude as well as the
concept of structural objects such as landmarks and cities to a chemical or drug space.
These characteristics when applied towards molecules include aspects such as size,
hydrophobicity, polarizability, electrostatic charge, structural flexibility or rigidity, and
dipole-dipole attraction [54]. Coordinates on the map are represented by t-scores
measured from a total of 423 “core” structures (representative drugs) and “satellite”
structures (molecules that contain characteristics way outside the drug space). Principal
component analysis (PCA) was used to predict scores for many other chemicals and
amino acids, building a comprehensive map of drug interrelationships [54]. The
ChemGPS tool is especially attractive when applied towards comparing different
molecules by simultaneously taking into account various dimensions and characteristics.
For applications in high-throughput phage display data, ROCS as well as
ChemGPS programs can be adapted to serve as valuable tools for identifying consensus
motifs in tissues of interest by not only taking into account amino acid sequence, but also
the overall shape and predicted biological activity of the peptide.
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Fig. 1-4.
4. Volume overlay of tyrosine and ttryptophan
ryptophan generated by ROCS OpenEye
Scientific Software. ROCS 3.2.0.4: OpenEye Scientific Software, Santa Fe, NM.
http://www.eyesopen.com.
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1.4

Hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is the 5th most common type of cancer found in

adults and the 3rd most common cause of cancer death [55]. There are approximately
630,000 new cases per year with about 80% of cases occurring in developing countries
including sub-Saharan Africa, East and Southeast Asia, and Melanesia [56]. Risk factors
for HCC include alcohol intake, hepatitis B virus, hepatitis C virus, exposure to toxins,
and obesity [55, 57]; however, chronic liver disease is the main etiological factor
associated with all cases of HCC [56]. A main characteristic of cirrhotic liver is a
decrease in hepatic vasculature which subsequently leads to a hypoxic environment in the
injured tissue. In response, cells upregulate hypoxia inducible factor-1α which goes on to
stimulate the production of additional angiogenic signaling molecules including VEGF
and several matrix metalloproteinases in an attempt to restore vascularization [58, 59].
Misregulation of these angiogenic and inflammatory signals can lead to damage of the
surrounding liver tissue, inhibition of tissue regeneration, and eventually the development
of HCC [55, 60].
Screening for HCC is performed by measuring serum levels of alfafetoprotein or
routine monitoring of the liver by ultrasound imaging [55]. Unfortunately, the disease is
usually detected when the tumor has progressed to an advanced and incurable stage.
Metastasis accounts for almost 90% of cancer associated mortality and is the least
understood aspect of cancer pathogenesis [61].
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1.4.1

Current standard of care for localized HCC

Treatment decisions for HCC are heavily based on tumor size and staging. In the
past, the only curative treatment for HCC was partial hepatectomy or liver transplantation
if the tumor was small (10-30% or cases) or local ablative therapy for patients who were
not surgical candidates [56]. Surgical resection of HCC tumors carries an increased
mortality rate when compared to resection for benign disease or liver metastasis from a
primary tumor not originating in the liver most likely due to the increased burden of
disease associated with cirrhosis [62]. Therefore, the ideal candidates for HCC resection
are those with early stage local disease lacking major vascular invasion and having well
managed cirrhosis.
Liver transplantation is an ideal therapy choice because this treatment modality
can mediate both the HCC as well as underlying liver damage. For HCC patients that
meet the criteria for transplantation (small solitary tumor without vascular invasion or
metastasis) the reoccurrence rate is around 5-15% with 5 year survival of over 70% [55,
63]. In fact, liver transplantation offers better disease-free and overall survival compared
with resection in patients that meet the criteria (66% 5-year survival for transplantation
compared to 46% 5-year survival for resections) [64]. Despite the improved outcomes
associated with transplantations, a major limitation is the availability of organs. Patients
on the waiting list for a liver transplant may have their cancer progress causing them to
be removed from the list.
An alternative to surgical interventions for treatment of HCC is local ablative
therapy. These treatments induce tumor cell death by modifying cell temperatures using
lasers, microwaves, radiofrequency, or cryoablation [55]. As these technologies have
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become more widely accepted, an increased amount of data has been collected as to the
outcomes and benefits. For small HCC tumors that have not metastasized, 5-year survival
rates of 40-70% have been reported for ablative therapy [55, 65]. Many patients will
undergo neo-adjuvant ablative therapy while on the waiting list for a transplant.

1.4.2

Molecular targeted drugs for advanced HCC

Unfortunately, many patients with HCC are not eligible for localized treatments
due to extra-hepatic metastasis and macroscopic vascular invasion. HCC is a chemoresistant tumor, therefore, systemic chemotherapy is not an effective treatment [66-68];
however, recent studies have shown that combination chemotherapy may enable the
tumor to become resectable [67]. Currently, the molecularly targeted drug, sorafenib,
which interferes with the mitogen-activated protein kinase signaling pathway has been
the only drug that increases the overall survival of patients with advanced HCC [56, 69].
Sorafenib counteracts angiogenic signaling critical for HCC tumor establishment, growth
and progression and has been successful in treating advanced HCC systemically. In a
clinical trial, the median overall survival for patients with advanced HCC treated with
sorafenib was 10.7 months compared to 7.9 months in a placebo group [69].
Due to sorafenib’s success as the first drug found to be effective in patients with
advanced HCC, many subsequent studies of molecularly targeted agents have been
performed with the hopes of improved patient outcomes. Despite a wide range of studies,
no therapeutic target has of yet shown efficacy in Phase III trials [55]. Given the
frequency and mortality associated with HCC and its metastasis, there is a clear need for
identification of improved therapeutic targets. HCC is commonly referred to as a
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hypervascular tumor [55, 70] and the recent advancement of anti-angiogenic molecular
therapies suggests that this may represent an ideal direction for improvements in the
treatment of advanced HCC.
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CHAPTER 2: MATERIALS AND METHODS

Reagents. The following primary antibodies were used: rabbit polyclonal antibacteriophage (Sigma), HRP-conjugated monoclonal anti-bacteriophage antibody (GE
Healthcare Life Sciences), rabbit polyclonal anti-giantin antibody (Abcam), rat
polyclonal anti-Orc2 antibody (Millipore), rabbit polyclonal anti-MEK1/2 antibody
(CellSignaling), and mouse monoclonal anti-58K antibody (Abcam). The following
secondary antibodies were used: HRP-conjugated anti-rabbit IgG, Cy3- conjugated antirabbit IgG (both obtained from Jackson ImmunoResearch Laboratories), biotinylated
anti-rabbit IgG (Vector Laboratories), FITC-conjugated anti-rabbit (Life Technologies),
FITC-conjugated anti-mouse (Life Technologies), and FITC-conjugated anti-rat (Life
Technologies). All synthetic peptides were commercially synthesized by PolyPeptide
Laboratories.

Cell culture. HEP3B, HEPG2, and SNU449 HCC cells (ATCC) were maintained in
Dulbecco's Modified Eagle Medium (DMEM) containing 10% fetal bovine serum (FBS),
100 units/mL penicillin, 100 ug/mL streptomycin, and 2 mM L-glutamine and cultured at
37°C in a humidified 5% CO2 incubator. Human Dermal Microvascular Endothelial Cells
(HDMECs) were maintained in EGM™-2 MV media containing 5% FBS and growth
supplements (Lonza Group, Ltd.) and cultured at 37°C in a humidified 5% CO2
incubator. 293FT cells (Life Technologies) were maintained in DMEM (high glucose),
10% FBS, 0.1 mM non-Essential Amino Acids, 6 mM L-glutamine, 1 mM sodium
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pyruvate, and 500 ug/ml Geneticin® (Life Technologies) and cultured at 37°C in a
humidified 5% CO2 incubator.

Preparation of phage libraries. Both CX7C and CX8C phage display random peptide
libraries were used for screening in patient 6. Primary unamplified phage libraries were
produced in order to decrease the likelihood of having an over-representation of certain
phage clones. Previously, the preparation of highly diverse phage libraries (109 peptide
permutations) has been described in [71]. Briefly, preparation is based on cloning DNA
fragments encoding for short peptides into the fUSE5 phage genome vector. The
fragments are cloned into the pIII capsid coat protein gene so that peptides will be
displayed on the surface of the phage and be able to interact with potential targets. First,
the fUSE5 plasmid is grown in Escherichia coli (E. coli) MC1061 F’-minus bacteria
maintained in LB- tet/strep medium [71]. This vector was initially designed to be noninfective due to the insertion of a disrupting “stuffer” sequence in the gene III reading
frame [71]. When the stuffer sequence is replaced by an in frame sequence, infectivity is
restored. fUSE5 vector was digested with the restriction enzyme SfiI which removed the
stuffer sequence and resulted in overhangs that are incompatible with one another. This
allows for unidirectional cloning of a DNA insert that is digested with the Bgl1 restriction
enzyme [21, 71]. Synthetic inserts were purchased as single strand oligonucleotides with
the sequence:
5’ CACTCGGCCGACGGGGCT (NNK)X GGGGCCGCTGGGGCCGAA 3’
Where N indicates random nucleotides (nt), K indicates either a G or T in order to
prevent the presence of stop codons in the sequence, and X represents the number of

22

amino acids desired in the peptide library. After ligation of the insert into digested
fUSE5, the vector was electroporated into MC1061 (at least 100 electroporations/library)
and amplified by shaking at 225 rpm at 37°C overnight.
Phage particles were amplified by infecting K91/ kanamycin (kan) bacteria grown
to log phase for 20 min at room temperature (RT). The infected bacteria were then
cultured in media containing 0.2 ug/mL tetracyclin (tet) in order to induce the phage tet
resistance gene. Following induction, bacteria were cultured overnight at 37°C in LB
media containing 20 ug/mL of tet and 100 ug/mL of kan. Cultures were next centrifuged
at 5,000 x g for 10 min and phage were precipitated with 16.5% polyethylene glycol and
3.3 M sodium chloride. After resuspending precipitated phage in phosphate buffered
saline (PBS), phage were quantified by bacterial infectivity assays on kan/tet selective
agar plates containing both 100 ug/mL kan and 40 ug/mL tet. Phage were diluted in PBS
and infected with log phage K91 E. coli in kan media for 20 min at RT. The bacteria were
plated in triplicate onto the kan/tet plates and incubated overnight at 37°C. Colonies were
counted to determine the transducing units (TU) per uL based on the phage starting
dilution [72]. The resulting library should contain 1011 – 1012 TUs of phage. Likewise,
about 100-1000 copies of each peptide can be expected to be represented in the library
[72]. Next, endotoxins were removed from the library as described in [73] because it
would be administered intravenously to a patient. Sterilized phage libraries were stored at
4°C in saline until administration.

Real time PCR for phage quantification (qPhage). Phage were quantified using the
qPhage protocol described in [45]. Briefly, phage samples were diluted 1:20. 5 uL of the

23

dilute phage sample was mixed with 1 x Fast SYBR Green PCR Mastermix (Applied
Biosystems) and 3.75 pmole of each of the primers:
forward:5’- TGAGGTGGTATCGGCAATGA- 3’
reverse: 5’- GGATGCTGTATTTAGGCCGTTT-3’
for a final reaction volume of 15 uL. These primers amplify a region on the tet resistance
gene located on the fUSE5 plasmid. The amplification program consisted of 50°C for 2
min, 95°C for 10 min, and 40 cycles of 95°C for 15 sec and 60°C for 1 min. A standard
curve was generated from serial 1:10 dilutions of a known concentration of phage (106 to
102 plasmids). The amount of phage in each reaction was determined by comparing the
amplification threshold for each sample to the standard curve. All amplifications were
run in triplicate.

Phage display screen in a patient. The study design was reviewed and approved by the
Institutional Review Board of the University of Texas M. D. Anderson Cancer Center
(MDACC # ID99-417) and follows the established ethics framework and guidelines [74,
75]. A 53 year-old male patient had been newly diagnosed with HCC and was on his way
to be treated at the University of Texas MD Anderson Cancer Center. During the trip, the
patient claimed to have chest pain and lost consciousness. At the emergency room, he
was found to be unresponsive and in cardiopulmonary arrest. The patient sustained
hypoxic brain injury and was made do not resuscitate. Following approval, a starting dose
of 1013 TUs of CX7C and CX8C phage library was intravenously injected into the patient.
Needle tissue biopsies were collected 15-30 min following infusion according to
Biosafety Level 1 protocols and kept on ice. The patient was then weaned from life-
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support systems and autopsy samples were collected 72 hr following phage library
injection after the patient was pronounced dead (Fig. 2-1). Tissue samples were handled
taking standard precautions associated with blood and bodily fluids.

Sequencing of individual phage. In order to confirm the correct peptide insert located
on phage after production or amplification, phage colonies were transferred into 30 uL of
10% glycerol for storage at -20°C. For a finalized phage preparation, phage were diluted
1:1000 in PBS. The PCR reaction contained 2 uL of the bacteria/glycerol mixture or
diluted phage, 8 pmol of forward and reverse primers specific for fUSE5:
forward: 5’- AGCAAGCTGATAAACCGATACAATT - 3’
reverse: 5’- CCCTCATAGTTAGCGTAACGATCT -3’
0.5 uL of 10 mM dNTPs, 2 uL of 25 mM MgCl2, 4 uL of 5 x GoTaq Polymerase buffer
(Promega), 2 units of GoTaq DNA polymerase (Promega), 0.4 uL of dimethyl sulfoxide
(DMSO), and water to a final volume of 20 uL. PCR reactions were carried out under the
following conditions: 94°C for 3 min, 35 cycles of 94°C for 10 sec, 60°C for 30 sec and
72°C for 1 min, followed by 72°C for 3 min. The DNA was sequenced by the Sequencing
Core Facility at the University of Texas M.D. Anderson Cancer Center.

High-throughput phage sequencing. High-throughput phage sequencing protocols were
adapted from [45]. Tissues obtained from in vivo phage display screens (25 mg/sample)
were ground using the Precellys®24 tissue homogenizer (Bertin Technologies). Tissue
digestion and DNA extraction was performed using a DNeasy Blood and Tissue Kit
(QIAGEN) and the final elution was done with 200 uL of sterile water. Amplification of
25

Fig. 2-1.
1. Schematic of phage display screen in a patient with HCC.
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the region of phage DNA containing the peptide insert was performed using primers
specific to the fUSE5 vector:
forward: 5’ TAG- CGCAATTCCTTTAGTTGTTCC 3’
reverse: 5’ TGAATTTTCTGTATGAGGTTTTGC 3’
We designed a system of tagging peptides extracted from specific tissues by performing
the initial DNA amplification with a unique three to six base pair sequence at the 5’ end
of the forward primer. Six base pair tag sequences had at least 2 base pair difference and
no more than 2 guanines or cytosines. The tagging system allows for the pooling of PCR
products from each tissue for sequencing in a single run and requires post sequencing
processing to determine the tissue of origin for each sequence. Phage DNA was amplified
using the Kapa HiFi DNA Polymerase Kit (Kapa Biosystems) for high fidelity PCR
amplification products. The PCR reaction contained 1.5 uL of 10 mM dNTPs, 5 uL of 5 x
GC Buffer, 2 uL of 25 mM MgCl2, 0.64 uL of KAPA HiFi DNA Polymerase, 16.5 pmols
of each primer, 5 uL of DNA, and water to a final volume of 25 uL. The reaction mix was
placed in a thermocycler and heated to 95°C for 2 min, with 35 cycles of 98°C for 20 sec,
60°C for 15 sec, and 68°C for 10 sec. After amplification, each sample was separated on
a 4% agarose gel where the desired product was between 140-150 nt in size. If
contamination at other sizes were present, the 140-150 nt bands were excised from the
gel and purified using a QIAquick Gel Extraction Kit (QIAGEN). Following purification,
samples were combined and purified using a DNA Clean & Concentrator™-5 Kit (Zymo
Research) and eluted 2 x with 25 uL of water. DNA was quantified and sent to the MD
Anderson Sequencing Core for high-throughput sequencing.
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Raw data processing and peptide extraction. Given the great number of sequences
generated using large-scale sequencing (on the order of 106 – 108 sequences per run), an
online sequence submission and analysis system for processing raw data was developed
using PERL scripts and a MySQL relational database management system. Peptide insert
sequences were extracted and sorted based on their tissue of origin and a newly
developed data mining tool was designed to allow for users to directly search for peptides
of interest. A tagging system was used to label peptides extracted from specific tissues by
performing the initial DNA amplification with a unique short sequence at the 5’ end of
the forward primer. Peptide insert sequences were extracted based on the identification of
both the flanking regions of the insert and the identification of this unique tag designating
the sample of origin. Sequence quality analysis was also performed to ensure the
reliability of each read. Exact base pair identification of the clone structure, identification
tag, amplification primers, and the flanking region of the insert was ideal; however,
minor sequencing discrepancies were allowed for in the clone structure, primer, tag, and
flanking sequence when extracting peptide sequences in order to utilize the full spectrum
of data. Additionally, saturation data analysis was performed to determine the coverage
of phage diversity for each tissue. The number of distinct peptides observed in a tissue or
sample of choice was compared to the total number of sequences evaluated for that tissue
or sample. This system allowed for a single multi-functional program for easy lab
member access and analysis of newly acquired data.

Bioinformatic analysis for peptide selection. A bioinformatic workflow was developed
to identify and prioritize lead peptide candidates for further validation (Fig. 2-2). Peptide
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Fig. 2-2.
2. Bioinformatic workflow describing the selection of lead motifs from peptide
sequences recovered from a phage display screen performed in a patient.
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sequences were gathered into groups, and assigned a unique label based on source tissue
and sample. Biologically similar groups were further aggregated into pools. Correlative,
non-correlative, and anti-correlative relationships between the pools were defined such
that tissue-specific features could be identified through statistical testing. Significance
scores were computed for sequences from each tissue, versus tissues belonging to
negatively correlated pools. Those with Fisher Exact Test p-values < 0.05 (one-sided)
were selected for further analysis. Peptide sequences selected for analysis were assigned
to clusters based on common tri-peptide segments. The clusters were then refined by
extending tri-peptide segments into patterns of 4, 5, and 6 amino acids, effectively
creating a tree of sub-clusters exhibiting incrementally greater sequence similarity.
Patterns that fail to yield Fisher test p-values < 0.05 versus sequences from negatively
correlated pools were next excluded. The remaining clusters were then prioritized
according to the total number of matching sequences and processed using ClustalW
alignment software (EMBL-EBI). The resulting sequence alignments were finally
manually reviewed for internal consistency. Sequences containing multiple tryptophans
and the sequences RGD or NGR were excluded from the analysis.

Multidimensional analysis for peptide selection. In a secondary bioinformatics
analysis, alternative properties of peptide inserts were taken into account to identify
enriched motifs in specific tissues (Fig. 2-3). Five different amino acid substitution
matrices were utilized to account for different amino acid properties including shape and
pharmacophoric activity [50, 54, 76]. Next, all unique forward and reverse motifs were
generated from the peptides found in all tissues. The size of motifs ranged from 1-8
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Fig. 2-3. Bioinformatic workflow describing the selection of lead motifs from peptide
sequences recovered from a phage display screen performed in a patient using
multidimensional amino acid properties.
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residues. Concurrently, a scaled frequency value was calculated for every unique peptide
in the data set where:
  





A normalization value (n) of 20,000 was used for the patient 6 data set because that was
the median number of peptides found in each tissue. A sum of the scaled frequencies was
calculated for all peptides found in each motif in each tissue. A ranking score was
calculated using two methodologies based on Bayesian smoothing [77]. First, a simple
score (S1) was calculated to select for motifs containing peptides that were found at a
high frequency in a tissue. Second, a combined score (S2) was calculated to select for
motifs containing many unique peptides all matching to a specific motif in the same
tissue.
Simple score: S
Combination score:
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A small increment was added to give higher priority to longer motifs over shorter motifs
containing the same peptides and the top motifs were selected for each analysis.

Principal component analysis. For several amino acid substitution strategies, a
similarity matrix was calculated based on given parameters of amino acid similarity and a
principal component analysis (PCA) was used to reduce the dimensionality and explain
the variance of the data. Analysis was performed by eigenvalue decomposition of the
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similarity matrix. Variable diagnostics, R2 and Q2, were calculated to determine estimates
of goodness of fit and prediction respectively. By graphing each attribute by each
component, a useful visualization of the data set was obtained and the 20 natural amino
acids were clustered into groups based on multidimensional similarity.

Internalization Assay. To examine phage internalization in cell lines, 104 cells/well
were plated on 16-chambered culture slides (BD Falcon) and allowed to attach and grow
overnight at 37°C. Following incubation, cells were blocked with 1% bovine serum
albumin (BSA) in media for 1 hr at 37°C then incubated with 108 - 109 TUs of
SGVGAASL displaying phage or insertless phage (as a negative control) for 24 hr at
37°C in media containing 2% FBS. Non-internalized phage were removed by washing
each well 5 x with 10% BSA in PBS, 5 x with glycine buffer (50 mM glycine, 150 mM
NaCl, pH 2.8) shaking at RT for 3 min each wash, and, finally, 3 x in PBS. Cells were
next fixed with 4% paraformaldehyde (PFA) in PBS for 5 min at RT followed by
washing 3 x with PBS. Next, cells were permeabilized by incubation with 0.2% Triton X100 in PBS at RT for 5 min, rinsed 5 x with PBS, and blocked with 1% BSA in PBS at
RT for 2 hr. The cells were then incubated with rabbit anti-bacteriophage antibody
diluted 1:500 in 1% BSA in PBS for 2 hr at RT followed by 5 washes with 1% BSA in
PBS for 2 min each. Secondary antibody (Cy3-conjugated anti-Rabbit IgG) was added to
the wells and allowed to incubate for 1 hr at RT. Wells were again washed 5 x with 1%
BSA in PBS for 1 min each. For fluorescent microscopy, cells were fixed in 4% PFA in
PBS for 5 min at RT, washed 2 x with PBS and mounted using VECTASHIELD with
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DAPI (Vector Laboratories). Images were acquired with an Olympus fluorescence
microscope.

Phage binding assay (BRASIL). Cell surface binding in vitro was performed using the
BRASIL method [28]. Briefly, cells were grown on 75 cm2 plates to 80% confluence and
washed 3 x with PBS. Cells were released from the plate by the addition of 4 mL of cold
PBS and 5 mM ethylenediaminetetraacetic acid (EDTA) to the plate. Cells were collected
into a 15 mL falcon tube and the final volume was increased to 15 mL with 1% BSA in
DMEM. Next, cells were counted and pelleted by centrifugation at 500 x g for 5 min.
Cells were resuspended, aliquoted in 5 x 105 cells increments and incubated on ice. A
phage solution was prepared in 1% BSA in DMEM at 1x 108 phage/tube. SGVGAASL
displaying phage or insertless phage (as a negative control) were used. The cell/phage
mixture was incubated on ice for 2 hr, then transferred carefully over 200 uL of nonmiscible organic lower phase (dibutyl phthalate: cyclohexane, vol/vol, 9:1; ρ = 1.03
g/ml), and centrifuged at 10,000 x g for 10 min at RT. During centrifugation, phage
particles bound to the surface of the cells were pulled down through the oil into the pellet
while unbound phage remained at the top of the oil. The tube was then snap frozen at 80°C for 15 min, and the bottom of the tube containing the pellet was removed and added
to 200 uL of log phase K91 bacteria for infection at RT for 30 min. Dilutions of infected
bacteria were plated on LB kan/tet plates and allowed to grow at 37°C overnight. The
next day, colonies were counted.
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Immunocapture phage binding assays. In a 96-well plate, 2 ug/mL of anti-giantin
antibody was plated per well and incubated overnight at 4°C. The next morning, unbound
antibody in solution was removed and remaining antibody was blocked with 200 uL/well
of 1% BSA in PBS at 4°C for 8 hr. Protein extract was centrifuged for 10 min at 4°C at
10,000 x g. After blocking, 20 µg of protein extract was added to each well and allowed
to incubate overnight at 4°C. The next day, the plate was washed 3 x with 0.05% Tween
in PBS and blocked for 1 hr in 200 uL 1% BSA at 4°C. Next, 1010 TUs of phage/well
were diluted in PBS (50 uL) and incubated for 2 hr shaking at RT. Solution in wells was
discarded and washed 12 x with 200 uL/well PBS. Quantification of phage was
performed in two ways. First, bound phage were eluted with 25 uL glycine buffer (50
mM glycine, 150 mM NaCl, pH 2.8) for 5 min at RT and particles were quantified using
qPhage. Second, a phage enzyme-linked immunosorbent assay (ELISA) was performed
by incubating wells with HRP-conjugated anti-phage antibody (diluted 1:4,000 in 50
uL/well) and washing wells 3 x with 0.05% Tween 20 and 0.01% Triton X-100 in PBS.
HRP detection was performed by incubation with TMB substrate (70 uL/well) for 30 min
followed by quenching of the reaction with 70 uL of 1M, 2 N H2SO4 and quantification
using an ultraviolet–visible (UV-Vis) spectrometer (450 nm).

Cultured cell protein extraction. Cells were plated on a 20 cm2 dish and allowed to
grow to at least 60% confluence at 37°C in a humidified 5% CO2 incubator. The
following steps were carried out on ice. Cell media was aspirated and cells were washed
2 x with chilled PBS. 500 uL/dish of chilled NP-40 lysis buffer (150mM NaCl, 50mM
Tris pH 8.0, 1% NP-40, 0.5% BSA, 1 tablet of Phosphatase Inhibitors Cocktail (Sigma),
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1 tablet of Protease Inhibitor Cocktail (Sigma)) was added dropwise to the surface area of
the plate. Next, dish sides were tapped gently then the dish was scraped using a sterile
cell scraper to remove attached cells. The buffer and cells were transferred to a 1.5 mL
Eppendorf tube and left 2 hr spinning at 4°C for lysis to occur. Following lysis, tubes
were centrifuged at 15,000 rpm for 10 min at 4°C to pellet debris. Supernatant was
recovered and stored at -80°C.

Tissue protein extraction. Human HCC tissue and normal human liver tissue samples
were obtained from ILS Bio. Tissue was ground in PBS and centrifuged at 4,000 g for 5
min at 4°C. The supernatant was stored at -80°C and the pellet was resuspended
overnight in 5 mL extraction buffer (1 mM phenylmethanesulfonylfluoride, 1 mM CaCl2,
1 mM MgCl2, 50 mM octylglucoside, 0.01% Triton X-100 in TBS). The next day, tubes
were centrifuged at 4,000 g for 5 min at 4°C and the pellet was resuspended in 1 mL
extraction buffer and transferred to 2 mL tissue homogenizing tubes containing 2.8 mm
stainless steel beads (Precellys hard tissue grinding MK28 beads, Bertin Technologies).
Tissue was homogenized in a Precellys®24 tissue homogenizer and incubated at 4°C
overnight for foam to go down. The next day, tissue was centrifuged at 10,000 rpm for 15
min at 4°C. The supernatant was filtered using Stericup® Steritop® Vacuum Filtration
Filters (0.45 um, Millipore) and protein concentration was measured. Protein was divided
into aliquots and stored at -80°C.

Plasma membrane protein fractionation. Cells were grown in complete media
(DMEM 10% FBS) to at least 60% confluence on three 20 cm2 dishes. The following
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steps were all performed on ice. Cell media was aspirated and cells were washed 2 x with
chilled PBS. Next, 5mL of chilled PBS was added to the plate and adherent cells were
scraped off of the plate using a sterile cell scraper. Cells in PBS were transferred to a
15mL tube and protein extraction was performed using Qproteome Plasma Membrane
Protein Kit (QIAGEN). The plasma membrane fraction was resuspended in 0.5% Triton
X-100 in PBS to a final volume of 400 uL. The protein concentration was measured and
plasma membrane proteins were divided into aliquots and stored at -80°C.

Peptide affinity chromatography. Receptors specific to selected peptides were isolated
using peptide affinity chromatography. First, peptides were conjugated to long arm amine
terminated magnetic beads (Bioclone Inc.). 1 mL of beads in a 15 mL falcon tube were
used per conjugation. Tubes were placed on magnetic stands to separate beads from
buffer. Buffer was removed and beads were resuspended in 3mL of coupling buffer (10
mM KH2PO4, 150 mM NaCl, pH 5.5). Beads and coupling buffer were allowed to stand
at RT on the magnetic stand. Buffer was removed and beads were resuspended in 3 mL
coupling buffer 2 additional times. After the final wash, beads were resuspended in 1 mL
of coupling buffer and combined with 1 mL of a 5 mg/mL solution of peptide diluted in
water. Peptide and beads were mixed thoroughly and 400 uL of 1-Ethyl-3-(3dimethylaminopropyl)carbodiimide (EDC, 4 mM) was made fresh and added. The
solution was left rotating for 24 hr at RT. The next day, beads were washed 3 x with 5
mL of water and an additional 3 x with wash/storage buffer (10 mM Tris, 500 mM NaCl,
0.1% BSA, 1 mM EDTA, 0.1% sodium azide, pH 7.5). Protein extract (10 mg/tube) was
added to peptide conjugated beads and incubated overnight spinning at 4°C (final volume
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adjusted to 5 mL with extraction buffer). The next day, beads were washed 10 x for 3 min
spinning with extraction buffer (the supernatant from first removal was saved and stored
at -20°C). Protein bound to peptide conjugated beads were eluted 3 x in 500 uL 0.1 M
glycine pH 2.2. Peptide conjugated beads were stored at 4°C in 10 mL PBS.

2-dimensional protein separation. Protein isolated by peptide chromatography was
quantified and interfering contaminants including detergents, salts, lipids, phenolics and
nucleic acids were removed using a 2-D clean-up kit from GE Healthcare Life Sciences
(2 µg of protein per cleanup). Following cleanup, pellets containing protein were
resuspended in 125 uL/ sample of rehydration buffer (8 M urea, 2% CHAPS, 40 mM
dithiothreitol, 0.5% IPG buffer (GE Healthcare Life Sciences), 0.002% bromophenol
blue). 2-D gel electrophoresis was performed using the ZOOM® IPGRunner™ System
(Life Technologies). The final gel was stained using SYPRO® Ruby Protein Gel Stain
(Life Technologies) and imaged using a 300 nm ultraviolet transilluminator.

Mass spectrometry analysis. Fractionated proteins isloated by peptide affinity were
separated by 2D SDS-PAGE and compared to control fractions. Unique bands were
excised from the SDS gels and digested with trypsin. After extraction of the peptides,
liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis was performed
by the Proteomics Core Facility at The University of Texas MD Anderson Cancer Center
and a list of peptide masses was generated. Sequence databases were cross-referenced
with the list of peptide masses to identify with high confidence proteins existing in the
original sample.

38

Protein quantification. Protein quantification was performed using a standard
bicinchoninic acid assay. Briefly, protein was diluted 1:10 and 1:100 in PBS. Serial
dilutions of a BSA standard were prepared. In a 96-well plate, 5 uL of each dilution was
added to a 1:50 dilution of working solution (ThermoScientific) and incubated at 37°C
for 30 min. UV-Vis was used to measure the wavelength at 562 nm. A standard curve
was generated from the BSA dilutions and sample concentration was extrapolated.

Western blot for protein expression. Purified protein was centrifuged at 4°C for 10 min
at 10,000 rpm to remove cellular debris. Each sample was mixed with 1x NuPAGE®
LDS Sample Buffer (Life Technologies) and incubated at 100°C for 5 min to denature.
Samples were then loaded onto a NuPAGE® Novex® 4-12% Bis-Tris Protein Gel (Life
Technologies) and run at 100 V for 7 min then 200 V for 40 min or until the loading
buffer ran to the bottom. Protein transfer from the gel to a nitrocellulose membrane was
performed using an iBlot® Gel Transfer Device (Life Technologies). The membrane was
rinsed with PBS then blocked in blocking solution (5% milk, 0.1% Tween-20 in TBS) for
30 min rocking at RT. Primary antibody was added to 5 mL of fresh blocking solution
and diluted as per manufacturer’s recommendation. Membranes were allowed to incubate
with primary antibody overnight at 4°C rocking. The next day, membranes were washed
3 x in washing solution (0.1% Tween-20 in TBS) for 5 min each with agitation. They
were then incubated for 1 hr rocking with HRP-conjugated secondary antibody at a
1:4,000 dilution in blocking solution. Again, the membrane was washed 3 x in washing
solution for 5 min on a shaker. Chemiluminescent detection was performed with
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Amersham ECL Prime Western Blotting Detection Reagent (GE Healthcare Life
Sciences).

Peptide dye conjugation. SGVGAASL peptide conjucation to IRDye 800 CW was
performed as per manufacturer’s instructions (LI-COR). In brief, equimolar amounts of
dye in DMSO were incubated with peptide in PBS at 4°C overnight on a rotating
platform under dark conditions. Dye conjugated peptides were purified by reverse-phase
high performance liquid chromatography (HPLC) using a Zorbax C18 HPLC column
(Agilent Technologies) in a gradient mixture of acetonitrile and water buffered with
triethylammonium acetate (50 mM, pH 6.0). Purified conjugate was dried using a vaccum
evaportator, quantified by UV-Vis (774 nm), and stored in the dark at -20°C until use.

Orthotopic mouse model of HCC. Orthotopic tumors were grown in the liver of male
BALB/c nude mice (4–5 weeks in age) using the HEP3B liver cancer cell line (2 x 106
cells in 50 uL) as described in [78]. When tumors reached the appropriate size (about 4
weeks following impantation), SGVGAASL peptide labeled with IRDye 800CW infrared
dye (excitation at 780 nm and emission at 794 nm) were injected intravenously at a dose
of 10 µg, 15 µg, 30 µg, or 50 µg into tumor-bearing mice. Images were acquired by a
Pearl Impulse Small Animal Imaging System (LI-COR) after 72 hr of circulation. All
animal procedures were reviewed and approved by the University of Texas MD
Anderson Cancer Center Institutional Animal Care and Use Committee.
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Immunohistochemistry of patient samples. A commercially available antibody was
used to examine the expression of giantin in patient samples by immunohistochemistry
(IHC). Sections from snap-frozen or formalin-fixed, paraffin-embedded human tissue
specimens were immunostained. Slides were deparaffinized, rehydrated, and washed.
Antigen retrieval was performed and endogenous HRP activity was eliminated with
hydrogen peroxide. Slides were treated overnight at 4°C with primary antibody diluted
1:100. Slides were then washed and incubated with HRP-conjugated anti-rabbit IgG
secondary antibody and developed with DAB substrate. Finally, slides were counterstained with hematoxylin, dehydrated, and mounted on coverslips for light field
microscopy.

Tissue microarray. Antibody titration experiments were conducted with an anti-giantin
antibody to establish antibody concentrations that would minimize background and
maximize signal detection. Serial dilutions were performed at 20 ug/ml, 10 ug/ml, 5
ug/ml, and 2.5 ug/ml on formalin-fixed, paraffin-embedded normal human tissues as well
as a sample of patient 6 HCC. Signal was detected using a biotinylated anti-rabbit
secondary and a VectaStain ABCAP kit with a Vector® Red Alkaline Phosphatase
Substrate Kit, which produced a fuchsia-colored deposit. Tissues were also stained with a
positive control antibody (CD31/vimentin) to ensure that the tissue antigens were
preserved and accessible for immunohistochemical analysis. Only tissues that exhibited
positive staining for CD31/vimentin were included in the remainder of the study. As a
negative control, the entire IHC procedure was performed on adjacent sections in the
absence of primary antibody. Staining intensity was recorded on a 0-4 scale (0=negative,
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1=minimal, 2=faint, 3=moderate, 4=strong). A series of human tissues including a 142
sample tissue microarray (TMA) obtained from BioChain (Z7020057) comprised of
normal liver (N=4), hepatocellular carcinoma (N=117), cholangiocarcinoma (N=14),
colon adenocarcinoma metastasis (N=1), and inflammatory liver tissue (N=6) as well as
18 single sections (N=3 each of 6 cancer types) were examined using the protocol
described above. Slides were stained at an optimized antibody concentration of 5 ug/ml
and imaged with a DVC 1310C digital camera coupled to a Nikon microscope. In
addition to staining intensity, localization of the staining pattern was determined
(cytoplasmic, membranous, nuclear, extracellular, and perinuclear expression).

Flow cytometry- live cells. Cells were harvested (300,000 cells/sample) and washed
with 1% BSA by centrifugation at 5,000 rpm for 2 min at 4°C. Next, cells were blocked
in a solution containing 1% BSA and 1% IgG from human serum (Sigma) for 15 min on
ice. Blocked cells were next incubated with primary antibody diluted as per
manufacturer’s instructions in 1% BSA and allowed to incubate for 30 min on ice. Cells
were washed 3 x with 1% BSA (250 uL/sample) by centrifugation at 5,000 rpm for 2 min
at 4°C. FITC-conjugated secondary antibody was diluted in 1% BSA (0.5 ug/sample,
final volume of 100 uL/sample) and allowed to incubate on ice for 20 min. Samples were
again washed 3 x with 1% BSA (250 uL/sample) by centrifugation at 5,000 rpm for 2
min at 4°C. Finally, cells were fixed by incubating with 4% fresh PFA for 5 min and
washed 3 x with 1% BSA (250 uL/sample) by centrifugation at 5,000 rpm for 2 min at
RT. Samples were resuspended in 300 uL 1% BSA for FACS analysis.
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Flow cytometry- permeabilized cells. Cells were harvested (> 500,000 cells/sample)
and washed with 1% BSA by centrifugation at 5,000 rpm for 2 min at RT. Next, cells
were fixed for 10 min in 4% fresh PFA and washed 3 x in 1% BSA by centrifugation at
5,000 rpm for 2 min at RT. Cells were then blocked in a solution containing 1% BSA and
1% IgG from human serum (Sigma) for 15 min and permeabilized by incubation with
Permeabilization solution (BD Cytofix/Cytoperm™ Fixation/Permeabilization Kit, 10 x
concentrate FBS and saponin, diluted 1:10 in distilled water prior to use) for 15 min at
RT. Cells were next incubated with primary antibody diluted as per manufacturer’s
instructions in Permeabilization solution and allowed to incubate for 30 min at RT. Cells
were washed 3 x with 1% BSA (250 uL/sample) by centrifugation at 5,000 rpm for 2 min
at RT. FITC-conjugated secondary was diluted in Permeabilization solution (0.5
ug/sample, final volume of 100 uL/sample) and allowed to incubate at RT for 20 min.
Samples were again washed 3 x with Permeabilization solution (250 uL/sample) by
centrifugation at 5,000 rpm for 2 min at RT. Finally, cells were fixed a second time by
incubating with 4% fresh PFA for 5 min and washed 3 x with 1% BSA (250 uL/sample)
by centrifugation at 5,000 rpm for 2 min at RT. Samples were resuspended in 300 uL 1%
BSA for FACS analysis.

Activated endothelial cells. HDMEC cells were cultured in EGM™-2 MV media
containing 5% FBS and growth supplements (Lonza Group, Ltd.). Cells were starved in
EGM™-2 MV Basal media not containing growth factors or FBS for 24 hr then activated
with 50 ng/ml recombinant human VEGF (Millipore Corporation) for 4 hr.
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shRNA cloning. The pLKO.1 puro vector was used to produce short hairpin RNA
(shRNA) specific to giantin. The vector contains an ampicillin resistance gene (AmpR)
for selection in bacterial cells and a puromycin resistance gene (PuroR) for selection in
mammalian cells. The human U6 promoter which drives RNA Polymerase III for
transcription of the shRNA transcript is located upstream of a 1.9 kb stuffer that is
released by digestion with enzymes EcoRI and AgeI. We designed oligos specific to
mRNA coding for giantin. General criteria that were met included identifying sequences
about 21 nt in length, avoiding regions close to start and termination codons, avoiding
regions with repeats and low complex sequences, and avoiding off-target effects on
alternative genes. The double stranded oligo structure is shown in Fig. 2-4a where red x’s
indicate sense sequences and green x’s indicate antisense sequences. A sequence
compatible with the AgeI digestion site (CCGG) was added to the 5’ overhang of the
forward oligo. On the 3’ end, a sequence (TTAA) was added to allow for compatible
ligation with an EcoRI digested overhang. In the center of both the forward and reverse
oligos is a spacer sequence (5’-CTCGAG-3’) that allows for the formation of a loop
when annealed (Fig. 2-4a). The oligos specific for the giantin mRNA transcript are
shown in Fig. 2-4b and each sequence was previously validated by Sigma Aldrich. Oligos
were dissolved in TE buffer (10 mM, pH 8.0) to a final concentration of 100 uM. An
annealing mixture was prepared by combining 10 uL of 10 x annealing buffer (1 M
NaCL, 10 mM EDTA pH 8.0, 100 mM Tris-HCl pH 8.0), 2 uL of the forward and reverse
oligos (2 uM each per annealing reaction), and 86 uL of water to a final volume of 100
uL. Annealing was performed in a thermocycler by heating to 93°C for 3 min, 80°C for
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a.
Forward oligo :
5’ CCGGxxxxxxxxxxxxxxxxxxxxxCTCGAGxxxxxxxxxxxxxxxxxxxxxTTTTTG

3’

Reverse oligo :
3’

xxxxxxxxxxxxxxxxxxxxxGAGCTCxxxxxxxxxxxxxxxxxxxxxAAAAACTTAA 5’

b.
Construct shRNA [GOLGB1.1]
GOLGB1.1(+) [58 nt] :
5’ CCGGgcttctgcttaatctgagaatCTCGAGattctcagattaagcagaagcTTTTTG 3’
GOLGB1.1(-) [58 nt] :
5’ AATTCAAAAAgcttctgcttaatctgagaatCTCGAGattctcagattaagcagaagc 3’
Construct shRNA [GOLGB1.2]
GOLGB1.2(+) [58 nt] :
5’ CCGGgcagacaatctcaagttgaaaCTCGAGtttcaacttgagattgtctgcTTTTTG 3’
GOLGB1.2(-) [58 nt] :
5’ AATTCAAAAAgcagacaatctcaagttgaaaCTCGAGtttcaacttgagattgtctgc 3’
Construct shRNA [GOLGB1.3]
GOLGB1.3(+) [58 nt] :
5’ CCGGgcactgaacatcaaagtagaaCTCGAGttctactttgatgttcagtgcTTTTTG 3’
GOLGB1.3(-) [58 nt] :
5’ AATTCAAAAAgcactgaacatcaaagtagaaCTCGAGttctactttgatgttcagtgc 3’

Fig. 2-4. Representation of oligos designed for construction of shRNA lentiviral
vector targeting giantin. a) Complimentary oligo schematic is shown. Red indicates
sense sequence; green indicates antisense sequence. b) Representation of three oligo pairs
designed to target the giantin (GOLGB1) mRNA transcript.

45

20 min, 75°C for 20 min, 70°C for 20min, 65°C for 20 min, and 40°C for 60 min. The
annealed oligos can be stored at -20°C for several months.
The pLKO.1 vector was next prepared for cloning. First, 1 µg of vector was
digested with AgeI and EcoRI (New England Biolabs) restriction enzymes at 37°C for 3.5
hr. The digested plasmid was run on a 0.8% agarose gel and the 7 kb band was purified
by gel extraction using the QIAquick gel extraction kit (QIAGEN). Purified DNA was
quantified and prepared for ligation. 50 ng of digested pLKO.1 was combined with 2 uL
of diluted (1:10 in water) annealed oligo, 1 uL of T4 DNA ligase (New England
BioLabs), 2 uL of 10 X T4 DNA ligase buffer, and water to a final volume of 20 uL. The
ligation was incubated at 16°C overnight. The next morning, 1-3 uL of the ligation was
transformed into 25 uL XL10-gold ultracompetent cells (Strategene) by electroporation.
The transformation product was plated on an agarose plate containing 100 ug/mL
ampicillin and incubated at 37°C overnight. The following day, 3-5 colonies from each
transformation were picked and incubated with 3 mL of LB+ ampicillin shaking
overnight at 37°C. A mini prep (QIAGEN) was performed on 1.5 mL of the bacterial
suspension and the remaining volume was stored at 4°C. DNA from the mini-prep was
sent for sequencing with pLKO primers:
forward: 5’ TGGACTATCATATGCTTACCGTAAC 3’
reverse : 5’ GTATGTCTGTTGCTATTATGTCTA 3’
After the sequence was confirmed, a maxi-prep (QIAGEN) was performed on the
remaining bacteria and DNA was quantified.
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Lentiviral production. The day before transfection (Day 1), 293FT cells were plated in a
10 cm tissue culture plate so that they would be 90-95% confluent the following day (2.5
- 5 x 106 cells in 10 mL of growth medium containing 10% FBS and no antibiotics). On
the day of transfection (Day 2), the culture medium was removed and replaced with 6 mL
of medium containing serum. DNA-Lipofectamine complexes were prepared for each
construct. Briefly, in a sterile 5 mL tube, 11 µg of lenti vector was added to packaging
vectors (1.8 µg of REV, 4.5 µg of PAK, and 2.7 µg of ENV (20 µg total)) in 1.5 mL of
medium without serum and antibiotics. In a separate sterile 5 mL tube, Lipofectamine
2000 (Life Technologies) was mixed gently before use and then diluted 50 ul in 1.5 mL
of medium without serum and antibiotics. The mixture was incubated for 5 min at RT.
Following the 5 min incubation, the diluted DNA was combined with the Lipofectomine
2000, gently mixed, and left to incubate for an additional 20 min at RT to allow DNALipofectamine complexes to form. Complexes were added drop-wise to each dish of cells
and mixed gently by rocking back and forth. Cells were incubated overnight at 37°C in a
humidified 5% CO2 incubator. The next day (Day 3), the medium containing DNALipofectamine 2000 complexes was removed and replaced with 6 mL fresh complete
culture medium without antibiotics. Cells were incubated overnight again at 37°C in a
humidified 5% CO2 incubator for virus particles to assemble. The supernatant containing
virus was harvested 48-72 hr post transfection (Days 4-5) simple by removing medium
and storing in a 15 mL capped conical tube. Because the virus was infectious at this
stage, extra precautions were taken. Supernatant was centrifuged at 3,000 rpm for 15 min
at 4°C to pellet cell debris. The supernatant was then filtered through a Millex-HV 0.45
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um polyvinylidene fluoride filter (Millipore) and separated into 1 mL aliquots. Unused
stocks were stored at -80°C.

Lentiviral infection. For lentiviral infection, adherent cells were seeded at a
concentration of 1 x 106 cells/well (final volume per well was 2 mL) in 6 well plates 1
day prior to infection. Cells were allowed to incubate overnight (37°C, 5% CO2). The
next day, media was removed and 1 mL of lentivirus containing polybrene at a final
concentration of 2 ug/mL was added to each well. Polybrene, a small positively charged
molecule, was added to neutralize the charge repulsion between virions and molecules on
the cell surface to allow for more efficient infection. Cells and virus were incubated
overnight (37°C, 5% CO2). 24 hr after infection, media was changed and replaced with
fresh media containing puromycin (5 ug/mL) to select for infected cells. Cells were
incubated in media and puromycin (37°C, 5% CO2) to allow for induction of the shRNA
and fresh media was added as needed. In order to observe phenotypic changes to cells
following infection with virus containing targeted and non-targeted shRNA, light field
microscopy was used to image cell morphology at time points following puromycin
selection. Furthermore, cells were harvested and protein extraction and Western blot
analysis was performed in order to confirm silencing of the target protein and examine
the expression of several other proteins.

Cell proliferation and adhesion. HEP3B cells were incubated with a shRNA lentivirus
targeting the GOLGB1 gene (shRNA GOLGB1.1). After 24 hr incubation at 37°C, 5%
CO2 with the virus, cells were selected for viral integration by a 48 hr incubation with
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puromycin. Cells were then split and plated on 96 well tissue culture E-Plates with microelectrodes integrated on the bottom (Roche) at 104 cells per well. The Roche
xCELLigence machine which measures electrical impedance in real time as cells attach
and grow on E-plates was programmed to take measurements every minute for 48 hr.

Statistical analysis. Statistical calculations were performed with InStat (GraphPad
Software) and data values are expressed as means ± standard error of the mean from
experiments performed at least in triplicate. For TMA data plots, the box extends from
the 25th to 75th data percentile, the line represents the data median, and the whiskers mark
the minimum and maximum data boundaries. P-values of less than 0.05 were considered
statistically significant.
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CHAPTER 3: RESULTS

3.1

High-throughput combinatorial peptide screen in a cancer patient
Vascular mapping allows for the opportunity to identify molecular markers

specific to different tissues. We performed a combinatorial peptide screen on a 53 yearold male patient (patient 6) who presented with HCC and clear cell renal cell carcinoma,
the most common type of renal cell carcinoma (RCC). Multiple primary tumors were
found in the liver indicating that the HCC was multifocal. Immunohistochemical analysis
of the HCC and RCC tissue sections from patient 6 determined that both specimens
represented independent primary tumors (Fig. 3-1). Hep Par 1 expression was positive in
HCC tissue sections but negative in the RCC tissue sections, indicating distinct primary
tumors [79]. The Pax8 marker is used to identify both primary RCC as well as metastatic
RCC [80]. Pax8 staining was solely positive in RCC tissue sections, further confirming
the tumors were independent in origin.
A large-scale preparation of CX7C and CX8C phage random peptide libraries was
administered into the patient once he had been formally declared brain dead according to
ethical guidelines. Thirty-minutes post-infusion, tissue biopsies (Table 3-1) were
collected including two samples from the HCC tumor. Autopsy samples (Table 3-2) were
also collected following 72 hr of systemic phage circulation. DNA was extracted from
each tissue and phage were amplified by PCR using primers containing a tag specific to
the tissue of origin. Amplicons were sequenced using the Roche 454 FLX platform (Fig.
3-2a) that can deliver reads of up to 1,000 basepairs with a typical overall throughput of

50

Fig. 3-1. Pathological
gical analysis of a patient with HCC and RCC.
Immunohistochemistry was performed on HCC and RCC tissue specimens obtained from
patient 6. HCC tissues were stained with antibodies against Hep Par 1 and Pax-8.
Pax RCC
tissue was stained with antibody against Pax
Pax-8.
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Table 3-1. Recovered peptide containing sequences from patient biopsy tissue
samples in a high-throughput phage display screen. Total peptide containing
sequences, number of different peptide containing sequences and the percentage of
different peptide containing sequences are shown.

Tissues
Bone marrow
Liver (normal)
Liver Tumor 1
Liver Tumor 2
Muscle
Prostate
Skin
White adipose
tissue
Yellow bone
marrow

Total peptide
containing
sequences
134,679
28,574
60,444
21,239
17,808
45,544
93,025
28,574

Different peptide
containing
sequences
122,440
16,602
24,793
19,508
16,621
30,359
29,669
16,602

%
Different
90.91
58.1
41.02
91.85
93.33
66.66
31.89
58.1

27,462

18,886

68.77
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Table 3-2. Recovered peptide containing sequences from patient autopsy tissue
samples in a high-throughput phage display screen. Total peptide containing
sequences, number of different peptide containing sequences and the percentage of
different peptide containing sequences are shown.

Tissues

Total peptide
containing
sequences

Different peptide
containing
sequences

%
Different

Adrenal gland

22,793

13,855

60.79

Aorta - ascending

12,000

6,985

58.21

Aorta – thoracic

21,253

11,518

54.19

Bladder

22,334

12,676

56.76

Cerebellum

21,717

13,067

60.17

Cerebrum

22,266

13,516

60.7

Coronary artery
(left)
Duodenum

10,022

6,418

64.04

21,213

11,975

56.45

Dura mater

21,333

12,211

57.24

Esophagus

18,570

11,374

61.25

Gall bladder

13,792

9,214

66.81

Heart – infarcted

21,239

11.996

56.4

Heart – normal

13,368

8,399

62.8

Kidney-normal

19,010

12,547

66

Kidney- tumor

1,479

958

64.8

Large bowel

13,594

8,965

65.95

Liver
Liver tumor 1
Liver tumor 2
Lung

99,373
31,941
13,063
13,525

36,860
25,749
8,291
9,117

37.09
80.61
63.47
67.41

Lung– lower right
lobe
Lymph node

16,864

10,545

62.53

118,670

84,080

70.85

Muscle

24,229

14,365

59.29

Pancreas

14,790

9,167

61.98

Prostate

15,654

8,261

52.77

Skin

23,861

14,211

59.56

Small bowel

46,660

29,146

62.46

Spleen

22,085

19,040

86.21

Stomach

12,682

7,650

60.32

Testis

15,707

9,704

61.78

Thyroid

23,787

13,103

55.08

White adipose tissue

16,708

10,881

65.12
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a.

b.

Fig. 3-2.
2. Schematic of phage DNA amplification from human tissue and resulting
amplicon layout. a)Phage DNA located in patient tissue were amplified using sequence
specific primers with a tag added to the 5’ end of the forward primer or three nucleotide
tag added to the 5’ end of the forward and reverse primers. Following amplification,
amplicons from all tissues
issues were pooled, 454 adaptor sequences were ligated to each end
of the amplicon and sequencing was performed. b) Recovered sequences contained the
index tag indicating the tissue of origin, flanking regions of fUSE5 vector, and the DNA
sequence encoding a CX7C or CX8C insert.
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450 megabases for amplicon sequencing. For phage display applications, over 1 million
sequences per run can be generated using this sequencing platform.
A system for online uploading and processing of raw sequencing data was
designed using PERL scripts and a MySQL relational database management system in
collaboration with Dr. Nalvo Almeida (Virginia Bioinformatics Institute, Virginia
Polytechnic University; current address: School of Computing, Federal University of
Mato Grosso do Sul) and Dr. Joao Setubal (Virginia Bioinformatics Institute, Virginia
Polytechnic University; current address: Department of Biochemistry, University of San
Paulo). (Fig. 3-3, 3-4). Raw sequencing and quality compressed data files were uploaded
to the phage system and passed to a process engine that confirmed the presence of a
peptide insert as well as a tag identifying the tissue of origin for each sequence (Fig 32b). Filters with varying stringency recognizing sequence match were employed to
maximize data recovery. Identified peptides were separated by tissue of origin then
passed through a quality score filter. Only reads containing quality scores with a > 95%
confidence in the sequence region encoding the displayed peptide were uploaded to the
database.
The database of recovered peptides was compiled and published online as an
application that enabled users to search for specific peptide sequences (Fig. 3-5), examine
the distribution of sequences (Fig. 3-6, 3-7), and identify peptide sequences that are
exclusively present in tissues of interest and not in other tissues (Fig. 3-8). This system
allows for a single multi-functional program for easy lab member access and analysis of
newly acquired data.
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Fig. 3-3. Schematic of raw data processing and database construction for sequencing
data recovered from high-throughput
throughput phage display screens.

56

Fig. 3-4.
4. Screenshot of user interface for online database of high
high-throughput
throughput phage
display screening data. Users are able to search by keyword, peptide sequence, run ID,
and tissue. The ability to upload new data for processing is also included.
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Fig. 3-5.
5. Output of peptide search function using newly designed online database for
high-throughput
throughput phage display screeni
screening data. The peptides matching the search are
listed as well as the DNA sequence, tissue of origin, PCR tag, location within the raw
sequencing data file, filter passed, and quality acceptance for each peptide.
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Fig. 3-6.
6. Run ID search for online databas
database of high-throughput
throughput phage display
screening data. Number of sequences and number of peptides are reported as an
overview. The filter by which each peptide was identified is included. A table of the total
and good quality peptides recovered from each tissu
tissuee in the run is also given. Options to
view all recovered peptide sequences is also available.
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Fig. 3-7.
7. Tissue search for online database of high
high-throughput
throughput phage display
screening data. Number of peptides and the filter by which each peptide was identified
are reported as an overview. Options to view recovered peptide sequences from the
searched tissue is also available. The option to calculate a saturation curve using the data
recovered from the searched tissue is included.
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Fig. 3-8.
8. Advanced Tissue search for online database of high
high-throughput
throughput phage
display screening data. The input matrix (left) allows users to include or exclude tissues
from which to search for unique peptides. The term unique peptide is defined as a peptide
that is only found in included tissues but not in excluded tissues. The option to remove
datasets such as peptides recovered from sequenced library is available. An example of
the search results
lts for unique peptides only found in biopsy bone marrow and autopsy
yellow bone marrow samples are shown (right). The number of times the peptide is found
is included as well as the number of sequences that passed the quality filter.
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We created saturation plots that depict the number of unique reads against the
total number of sequences (Fig. 3-9). Analysis of large-scale derived sequences (a total of
1,242,931 sequences distributed among 41 samples, Table 3-1, 3-2, 3-3) elucidated a
non-random distribution of peptides among tissues (Fig. 3-9). In the data recovered from
each tissue, the number of unique sequences stabilized as the number of total sequences
increased. This finding confirmed the feasibility of this methodology for the isolation of
selective peptides targeting normal and diseased organs (Fig. 3-9). Furthermore, for the
sequenced library, the number of unique sequences increased linearly with the number of
total sequences recovered, demonstrating that the initial library was informative and not
affected by sequence artifacts that may arise during preparation and recovery.

3.2

Bioinformatic selection of tissue specific peptides
Advanced bioinformatics tools are essential for efficient processing and

identification of tissue specific peptide motifs. In our study, millions of peptide sequences
were recovered utilizing next-generation sequencing technology. The recovered data set
was subjected to multiple levels of stringent bioinformatic analysis to more effectively
select for significantly enriched motifs in tissues of interest. In an initial analysis,
peptides were clustered into four amino acid long motifs to identify peptides that were
significantly enriched in HCC samples (workflow represented in Fig 2-2). From this data
set, 113 peptides were determined to be specific to four samples of human HCC tumor
tissue that were recovered including two samples during biopsy and two samples during
autopsy. In the two recovered autopsy samples, 10 and 20 peptides were selected from
top motifs while in the biopsy samples, 15 and 12 peptides were selected (Table 3-4a).

62

Fig. 3-9.
9. Saturation curves for peptide sequences recovered from human liver and
HCC autopsy samples following a high
high-throughput
throughput phage display screen. Saturation
curve for CX7C library is also included. In the graphs, the total number of sequences
versus the number of different sequences is shown.
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Table 3-3. Overview of recovered peptide containing sequences from highthroughput phage display screen in a cancer patient. All 40 tissues were compiled and
sequencing results from naïve, uninjected CX7C and CX8C libraries are included. Total
peptide containing sequences, number of different peptide containing sequences and the
percentage of different peptide containing sequences are shown.

Tissues
41 total
CX8C library

Total peptide
containing
sequences
1,242,931
77,888

Different peptide
containing
sequences
759,340
73,906

%
Different
61.09
94.89

CX7C library

81,458

77,462

95.09
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Table 3-4. Tissue-specific peptides selected from liver tumor tissue. a) Peptides
specific to single tissues. b) Peptides specific to multiple tissues. c) Lead peptide
sequences selected from liver tumor tissues. Peptide in red was selected for further
biochemical validation.
a.
Single tissue specific peptides
Sample

Peptides selected

HCC- autopsy sample 1
HCC- autopsy sample 2
HCC- biopsy sample 1
HCC- biopsy sample 2

10
20
15
12

b.
Multi-tissue specific peptides
Sample 1

Sample 2

Peptides selected

HCC- autopsy sample 2
HCC- autopsy sample 2
HCC- autopsy sample 2
HCC- autopsy sample 1
HCC- autopsy sample 1
HCC- biopsy sample 1

HCC- autopsy sample 1
HCC- biopsy sample 1
HCC- biopsy sample 2
HCC- biopsy sample 1
HCC- biopsy sample 2
HCC- biopsy sample 2

9
23
6
5
5
8

c.
Selected Peptide Sequences
RIHSSAYR (liver tumor aut2)
LHTRYRLS (liver tumor aut2)
SGATPPVR (liver tumor aut2)
VEMSARS (liver tumor aut2)
LSNVPSRT (liver tumor aut2)
LRCMSPT (liver tumor aut1)
RGPVSGY (liver tumor aut1)
RSDLKGFS (liver tumor aut1)
SGVGAASL (liver tumor bio1)
AVRGGGPV (liver tumor bio1)
PERARREI (liver tumor bio1)
PGAGSVKV (liver tumor bio2)
ARVIPRA (liver tumor bio2)
SMLRSER (liver prim bio2)
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Furthermore, multiple HCC samples were combined into correlative groups and peptides
found in top motifs were selected (Table 3-4b). From the 57 single tissue-specific
peptides reported in Table 3-4a, 14 peptides were selected based on qualitative analysis
including the omission of peptides containing tryptophan, RGD, and NGR in their
sequence (Table 3-4c). RGD and NGR sequences were excluded as these are well
described tumor vasculature specific tri-peptide motifs [81, 82]. The peptide,
SGVGAASL, clustered to the motif GAAS, was selected for biochemical validation and
characterization as an HCC targeting peptide in Chapter 3.3.

3.2.1

Generation of amino acid substitution matrices

After an initial bioinformatics analysis, a more comprehensive study was
performed to account for multidimensional properties of amino acids including
bioinformatic (1D), physiochemical (2D), structural and pharmacophoric (3D), and
“druglike” properties (workflow represented in Fig 2-3).
The 1D clustering algorithm was developed by adapting the BLOSUM62 amino
acid substitution matrix. Values in the BLOSUM62 matrix are based on examination of
the probability of amino acid substitution in aligned related proteins [50]. A similarity
matrix comparing each amino acid was generated and a three dimensional PCA was
performed to cluster amino acids into substitution groups (Fig. 3-10a,b). The substitution
matrix derived from the BLOSUM62 analysis is shown in Table 3-5a.
In addition to a bioinformatics approach, amino acids were grouped based on the
physiochemical properties including size, charge, hydrophobicity/hydrophilicity, and

66

a.

b.

Fig. 3-10.
10. BLOSUM62 analysis for amino acid substitution. a) similarity matrix for all
20 amino acids (abbreviated in single letters) b) Principal component analysis performed
on BLOSUM62 similarity matrix. Three components were used. R2=0.68, Q2=0.35.
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Table 3-5.
5. Amino acid substitution matrices. a) BLOSUM62, b) 2-dimensiona
dimensional amino
acid characteristics, c) ROCS, d) ChemGPS
ChemGPS-4D, e) ChemGPS-9D
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aromaticity (Table 3-6). Based on these molecular properties, seven groups were
qualitatively identified (Table 3-5b).
Next, structural and pharmacophoric properties were considered using the ROCS
software where each property was given a score between 0-1 (0 indicating dissimilarity
and 1 indicating similarity) [76]. The combined scores were used to generate a similarity
matrix with a value of 2.0 representing maximum similarity with regards to the two
examined properties (i.e. the same amino acid) (Fig. 3-11a). A three-dimensional PCA
was performed to group amino acids based on the generated similarity matrix (Fig. 311b) and a unique, more stringent amino acid substitution matrix was defined (Table 35c).
Finally, a previously described “drugspace” map constructed by applying
geographical conventions such as dimensions and objects when examining a chemical
space was used to define two additional amino acid substitution matrices (ChemGPS4
and 9, Table 3-5d,e) [54]. Both a 4-dimensional PCA as well as a 9-dimensional PCA on
this data was performed to group amino acids based on similarity within the “drugspace.”
Using these unique amino acid substitution matrices, consensus motifs in tissues
of interest can be defined by not only taking into account amino acid sequence, but also
the many physical and biological properties influenced by motif shape and activity.

3.2.2

Selection of tissue specific peptides by multidimensional analysis

Using our five defined amino acid substitution matrices, an analysis of tissue
specific motifs was performed utilizing the patient combinatorial peptide screen data. For
each substitution matrix, identified motifs were ranked using two different scoring

69

Table 3-6. Grouping of amino acids based on 2-dimensional characteristics
including size, charge, aromaticity, and hydrophobilicity.

Amino acid
A
G
P
D
E
F
W
Y
C
I
L
M
V
H
N
Q
K
R
S
T

Properties
small
small
small
acceptor, anion
acceptor, anion
aromatic
aromatic, donor
aromatic, donor, acceptor
hydrophobic
hydrophobic
hydrophobic
hydrophobic
hydrophobic
donor, acceptor
donor, acceptor
donor, acceptor
donor, cation
donor, cation
donor, acceptor, small
donor, acceptor, small

70

a.

b.

Fig. 3-11.
11. ROCS scoring based amino acid substitution analysis. a) Similarity matrix
for all 20 amino acids (abbreviated in single letters) based on ROCS scoring of similarity
between amino acid shape and pharmocophoric properties. b) Principal component
analysis performed on ROCS derived similarity matrix. Three components were used.
R2=0.73, Q2=0.41.
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algorithms: one placing greater weight on peptide frequency within a motif (simple
score), and one placing greater weight on peptide diversity within a motif (combined
score). The top 100 motifs were identified using each amino acid substitution matrix and
each pattern ranking score resulting in a total of 1,000 top ranked motifs for each tissue
recovered from our patient screen. The top motifs identified in these analyses as well as
the number of unique peptides clustered to those motifs are shown in Tables 3-7 through
3-16. Tables include the maximum score (simple or combined) of the top motif in each
tissue as well as an example peptide of that motif. In tissues with high recovered peptide
diversity such as bone marrow and lymph node, the score of the top motif was
consistently less than tissues where a lower diversity of peptides were recovered (i.e.
prostate and skin). In particular, the top motifs selected from peptides recovered in liver
tumor tissue had some of the highest simple and combined scores, indicating that
selection of peptides occurred in this tissue and further establishing the potential of these
motifs for specificity to tumor vascular beds. Examination of peptides clustering to top
motifs across all 10 analyses identified a subset of common peptides (Table 3-17).
Common peptides selected in analyses using the simple score ranking are shown in Table
3-18 and using the combination score ranking in Table 3-19. Peptides identified in
multiple analyses may lead to an increase in confidence regarding targeting specificity
and significance in the tissue of interest.
To further prioritize top scoring motifs selected in liver tumor tissue, PepBank
software was used to identify biologically relevant peptides [83]. Peptides sharing
sequence homology to hormone proteins are listed in Table 3-20 with the relevant
sequence matching to selected liver tumor specific motifs shown in bold. A functional
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Table 3-7. Summary of motif selection analysis performed using the BLOSUM62
amino acid substation matrix and simple score ranking for all patient tissues
recovered.

Tissue
Adrenal Gland
Aorta
Bladder
Bone Marrow
Bowel
Brain
Coronary Artery
Duodenum
Duramater
Esophagus
Fat
Gallbladder
Heart
Kidney
Liver
Liver Tumor
Lung
Lymph Node
Muscle
Pancreas
Prostate
Skin
Spleen
Stomach
Testis
Thyroid
Yellow Bone Marrow

BLOSUM62 Simple Score
Highest
Unique Peptides Scored Motif
217
SFCRGLG
124
RSFAFLR
196
RFDLRLL
3938
RLFGxFL
302
ARSAxLDA
250
SRDGADR
144
DFFLALA
250
DFRGRFA
207
RADFSD
195
LRRxHxxH
319
RLLHLDR
168
RLRSGRL
232
SSDxSRLL
201
RRCSCGL
549
LGLRCCC
235
SFRRAA
325
DARSFSA
676
HxxLLxLD
227
SxCRFRL
216
HLFLALG
168
GAAFFSD
191
LxACCDL
280
GAxFAxC
369
LASAxRAL
188
RxLLRGSG
257
DRDxxFFD
632
SFGDLAD
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Maximum
Score
0.284
0.475
0.478
0.091
0.378
0.389
0.589
0.489
0.452
0.453
0.425
0.357
0.538
0.297
0.245
0.573
0.460
0.160
0.342
0.458
0.616
0.389
0.410
0.509
0.358
0.330
0.265

Example
Peptide
GVGRCYP
QMFTWSR
VMRVEYRC
RMYGSFLG
TRPAPLET
PREGTEQ
EFFIAVT
AFRGRFE
RARAEYSE
HTLHNRRV
RVLHVNR
LRGSRMQF
SSNDPRLL
MGCPCQR
CCCRVGL
ATKRWPTH
EARPWST
HDGLLNME
SVCRFRL
GVTVWLH
DSYWATG
VDCCAIV
CETWNAGT
LTRLAPAV
GSGQILAR
EYYAGERE
GNTLEGWS

Table 3-8. Summary of motif selection analysis performed using the BLOSUM62
amino acid substation matrix and combination score ranking for all patient tissues
recovered.

Tissue
Adrenal Gland
Aorta
Bladder
Bone Marrow
Bowel
Brain
Coronary Artery
Duodenum
Duramater
Esophagus
Fat
Gallbladder
Heart
Kidney
Liver
Liver Tumor
Lung
Lymph Node
Muscle
Pancreas
Prostate
Skin
Spleen
Stomach
Testis
Thyroid
Yellow Bone Marrow

BLOSUM62 Combo Score
Highest
Unique Peptides Scored Motif
183
SFCRGLG
114
LxSLLCL
192
RGDASFF
2501
LRLxDLF
391
DxRRFGA
145
SDRRSSDR
173
CxSLFxC
180
RAxGGLxG
157
FxHxRGxD
223
SGxSARxL
652
LLGALCG
212
SDRFxLLL
158
RDxRGCL
228
DDRxDAD
864
FRxAFSD
979
RxGLxGSA
102
SDxDGxxD
1849
DxLFARA
857
LRxFSLxA
157
LGLCGSAA
305
GAxFFSD
386
SFxDGRA
644
SSLLAxF
176
SFGGAxF
177
RxCRAGD
235
RFGFRDRA
861
SxSDGSF
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Maximum
Score
0.043
0.112
0.076
0.016
0.096
0.085
0.133
0.082
0.109
0.094
0.127
0.098
0.129
0.062
0.031
0.162
0.126
0.018
0.106
0.098
0.241
0.068
0.087
0.133
0.059
0.046
0.074

Example
Peptide
GVGRCYP
MCLVSVMS
RGDTSWY
LKVRELFS
AGFRRWD
RNSSRRDS
CLYVSYC
GVIGGITR
WFHARGLE
PGHPAQEL
RGCLAGLV
SERYTVLL
RDWRGCV
EEREDAEL
ESYARRF
QVGLGGST
SDADGMQD
ARAWIKDR
MRHFPMPT
ATSGCVGV
DSYWGAG
AAQGNDFP
FIAILSS
WPAGGYS
WRGCQAGN
TRERFGWR
SFPGDPRS

Table 3-9. Summary of motif selection analysis performed using the 2-dimensional
properties amino acid substation matrix and simple score ranking for all patient
tissues recovered.

Tissue
Adrenal Gland
Aorta
Bladder
Bone Marrow
Bowel
Brain
Coronary Artery
Duodenum
Duramater
Esophagus
Fat
Gallbladder
Heart
Kidney
Liver
Liver Tumor
Lung
Lymph Node
Muscle
Pancreas
Prostate
Skin
Spleen
Stomach
Testis
Thyroid
Yellow Bone Marrow

2D Simple Score
Highest
Unique Peptides Scored Motif
285
LRRFNLRF
282
RSFSFxN
269
RFDLRLL
3909
SFLSFA
499
SxAAALDS
348
NDAADRA
310
NFFLSLA
285
NDAAAASL
250
SANRNAS
297
SALLLLRF
408
RxNxxNFL
233
NLRSARL
314
SSNDARL
337
RSAAxNLD
1028
RDDARLL
349
SSxRFxDS
275
SSFARAD
1232
NRxLLSLD
525
NxRFRLL
183
NLFLSLA
388
DSFFAAA
320
SxxSALNR
450
ASAFSALA
441
LSAALNAL
179
RALLNxSA
294
RDAxFFD
568
SFxLADDA
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Maximum
Score
0.260
0.474
0.472
0.096
0.378
0.396
0.578
0.450
0.421
0.391
0.418
0.368
0.534
0.308
0.220
0.515
0.458
0.163
0.325
0.440
0.605
0.375
0.404
0.506
0.353
0.341
0.267

Example
Peptide
LRKWNVRW
QMFTWSR
VMRVEYRC
TAFSVFS
TRPAPLET
AREGGEND
QWYVSVGE
VSPAGAEN
TANRQGSQ
TALMIVRW
RFQELQFV
LRGSRMQF
VLRGEHSS
EVNMAPSR
REDGRVLN
SEWWRRST
EARPWST
QRRMLTMD
VIRFRCH
QIYVSIG
DSYWGAG
KQVASSAS
GTPWTGCG
CTGGCQAL
GSGQILAR
REAGWYEM
GEEAVVYT

Table 3-10. Summary of motif selection analysis performed using the 2-dimensional
properties amino acid substation matrix and combination score ranking for all
patient tissues recovered.

Tissue
Adrenal Gland
Aorta
Bladder
Bone Marrow
Bowel
Brain
Coronary Artery
Duodenum
Duramater
Esophagus
Fat
Gallbladder
Heart
Kidney
Liver
Liver Tumor
Lung
Lymph Node
Muscle
Pancreas
Prostate
Skin
Spleen
Stomach
Testis
Thyroid
Yellow Bone Marrow

2D Combo Score
Highest
Unique Peptides Scored Motif
208
LRRFNLRF
221
RAASSANA
210
ALxANFLA
2494
SxDRNF
498
LLARSNA
160
NSAxSFD
260
LLLAAALD
297
DDNSAxxA
177
DRDRxAND
303
RASFNDA
580
NAxSRSA
196
SDRFxLLL
214
LAxALNFA
219
RxSALRDN
833
RxAxNLNN
1001
RxFxLNNA
209
RARxDDxL
1734
LFSDAA
921
DARLAxLA
139
SDFxAxFA
501
LSxFLDF
417
RxFxAARF
871
RLNxxASN
194
LSADRxLL
215
SSFDRxR
206
RRLLLSNL
746
RAFAxLxD
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Maximum
Score
0.039
0.096
0.071
0.015
0.105
0.091
0.120
0.070
0.093
0.074
0.112
0.098
0.169
0.056
0.029
0.191
0.114
0.018
0.100
0.091
0.231
0.062
0.115
0.090
0.071
0.046
0.076

Example
Peptide
LRKWNVRW
KGATTGHG
PVWQGRVP
SWHREIT
APNTRAVL
AQSGLTWE
ECPGGCMV
DDQSATLG
ERERLGHE
PEHWSAKR
PPTKSPAH
SERYTVLL
GFQLGGGL
QDRLASTR
RRGHQVNN
RYWGLHHA
RARNEEGI
GPESFLRV
GMRAVRAE
GFRGRWDT
SWDMFDSI
RGFFAGRF
RLNSLGSQ
VSGDKGVV
MTSWDKYR
RRLVITNV
RAYGFVGD

Table 3-11. Summary of motif selection analysis performed using ROCS derived
amino acid substation matrix and simple score ranking for all patient tissues
recovered.

Tissue
Adrenal Gland
Aorta
Bladder
Bone Marrow
Bowel
Brain
Coronary Artery
Duodenum
Duramater
Esophagus
Fat
Gallbladder
Heart
Kidney
Liver
Liver Tumor
Lung
Lymph Node
Muscle
Pancreas
Prostate
Skin
Spleen
Stomach
Testis
Thyroid
Yellow Bone Marrow

ROCS Simple Score
Highest
Unique Peptides Scored Motif
152
VPDPNxS
120
RxFSFLN
143
RFDLRLL
3684
PVRSxxL
150
FVVVPxA
107
PRxGADN
181
NFFLxLA
118
DFRGxFA
147
SSxVGGA
218
SxLxVVRF
302
NNSxxFL
315
VRGSRVN
194
SxNxPRxL
148
RNLPLGL
663
SxLxSPA
169
SSxRFxDS
214
SSFPxAD
505
RxDVxSVD
204
FLSxRRD
179
RLFVSVG
192
DSFFAA
165
VVALLDV
323
GxPFSGxG
160
VANxxPxL
86
GLGALDRD
129
DRDxxFFD
338
VSxxxGNS
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Maximum
Score
0.295
0.475
0.484
0.100
0.446
0.398
0.594
0.490
0.462
0.391
0.432
0.413
0.538
0.297
0.248
0.515
0.460
0.156
0.312
0.455
0.610
0.418
0.414
0.512
0.390
0.330
0.286

Example
Peptide
VPDPQIS
QMFTWSR
LLRLDWR
PVRSLEMG
AKPIVVWA
PREGAEQ
NYFLTLA
AFRGRFE
SSSIGGA
TALMIVRW
ANNSPGWL
QVRSGKV
SSNDPRLL
MGCPCQR
GAPSRLRS
SEWWRRST
EARPWST
EVTNVEDH
ERRLSLYS
GVTVWLRR
VESFWAAS
VDCCAIV
GFGSWPSG
LTPAVQAV
ERELAGLG
EYYAGERE
SQGARRSV

Table 3-12. Summary of motif selection analysis performed using ROCS derived
amino acid substation matrix and combination score ranking for all patient tissues
recovered.

Tissue
Adrenal Gland
Aorta
Bladder
Bone Marrow
Bowel
Brain
Coronary Artery
Duodenum
Duramater
Esophagus
Fat
Gallbladder
Heart
Kidney
Liver
Liver Tumor
Lung
Lymph Node
Muscle
Pancreas
Prostate
Skin
Spleen
Stomach
Testis
Thyroid
Yellow Bone Marrow

ROCS Combo Score
Highest
Unique Peptides Scored Motif
111
VSLxLLL
129
VxxVVLxD
127
PVxGNFVP
2431
RxDxDVF
302
SxLPAPR
135
SDRRSSxR
127
RVLAGLG
87
VAAFPG
246
DRGxRDRD
97
VNxxxVGN
566
SxAVxDP
189
SDRFxVLL
136
RxVSVVR
239
VLLNxVL
838
GSVARF
1027
RxFxVxNG
137
RxxNRDP
1679
VLFGAR
978
VSxAxDG
101
VGVLGxSA
297
VVNxxRSV
180
PRSRVL
641
VVRNSL
116
ARxFxxDA
105
GLGALDRD
176
VNSVVLRR
780
SDxPxVG
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Maximum
Score
0.044
0.126
0.074
0.020
0.096
0.081
0.136
0.074
0.088
0.078
0.148
0.098
0.154
0.060
0.033
0.164
0.150
0.019
0.114
0.098
0.255
0.056
0.139
0.118
0.080
0.046
0.101

Example
Peptide
WLLLDMSI
EWMVVLGV
PVWQGRVP
REDPDVYT
VTRLPAPR
SDRRTSLR
RVCAGLG
VAAYPGA
ERERLGHE
VQLGQIGN
GSRAVMEP
SERYTVLL
SRVVSVER
LLVLNLLV
GTVARFC
KGYLIGNG
PDRNSRRV
KVLYGARS
VSTAREGS
ATSGCVGV
VVQEGRSI
LPRSHVLL
YIIRQSLD
AESFWLRA
ERELAGLG
RRLVITNV
SEPPRVGR

Table 3-13. Summary of motif selection analysis performed using ChemGPS-4D
amino acid substation matrix and simple score ranking for all patient tissues
recovered.

Tissue
Adrenal Gland
Aorta
Bladder
Bone Marrow
Bowel
Brain
Coronary Artery
Duodenum
Duramater
Esophagus
Fat
Gallbladder
Heart
Kidney
Liver
Liver Tumor
Lung
Lymph Node
Muscle
Pancreas
Prostate
Skin
Spleen
Stomach
Testis
Thyroid
Yellow Bone Marrow

ChemGPS-4D Simple Score
Highest
Unique Peptides Scored Motif
155
VPNPNVS
209
RSFSFVN
169
VVRVNFR
3463
SFVSFA
252
FVVVPxA
267
PRNAANN
211
NFFVSVA
241
FxPSFC
247
VRVVAVRS
249
SxVVVVRF
442
FRRSACF
230
VKASRVN
298
VxRPNxSS
237
VRNNVxAV
657
VAVRCC
281
SSxKxSNS
265
SSFPRAN
1137
RxNxVSVN
209
VFKVAS
171
VRVNAAFA
183
NSFFAAA
245
VVACCNV
365
AxxFxACA
320
VSPAxNAV
180
RVPRxPxA
232
NRNAxFFN
500
NxxNVRxF

79

Maximum
Score
0.295
0.475
0.458
0.099
0.410
0.397
0.566
0.453
0.433
0.391
0.406
0.405
0.538
0.313
0.248
0.526
0.455
0.154
0.348
0.436
0.596
0.418
0.407
0.509
0.361
0.329
0.272

Example
Peptide
VPDPQIS
QMFTWSR
AHFDVRIV
TAFSVFS
WVMMPLGR
PRNGAQDS
QWYVSVGE
FGPTFCL
SRMGIMRV
TALMIVRW
FRRSGCF
RDVRTGKL
SSNDPRLL
VREDVRAI
VGLRCCL
TTRKFSDT
EARPWST
QVTLKQAR
TGLKFLRQ
GWAGEMRI
TNSFYGAA
VDCCAIV
ARLWDGCG
VTPALEAL
GSPSRPLR
QWFAADRE
YRRVEAGD

Table 3-14. Summary of motif selection analysis performed using ChemGPS-4D
amino acid substation matrix and combination score ranking for all patient tissues
recovered.

Tissue
Adrenal Gland
Aorta
Bladder
Bone Marrow
Bowel
Brain
Coronary Artery
Duodenum
Duramater
Esophagus
Fat
Gallbladder
Heart
Kidney
Liver
Liver Tumor
Lung
Lymph Node
Muscle
Pancreas
Prostate
Skin
Spleen
Stomach
Testis
Thyroid
Yellow Bone Marrow

ChemGPS-4D Combo Score
Highest
Unique Peptides Scored Motif
129
PFCRAVA
170
SANAARAN
136
PVxANFVP
2335
VAASSxxN
423
SxVPAPR
147
SNRRSSNR
102
RVARCRAP
155
VSFRVAxS
185
NRNRxARN
235
VSRPPNV
647
VVxVNNxF
180
VVVxFRNS
187
VAxAVNFA
336
NNxSxRKA
874
SxFARSF
1212
SSNAVRA
123
CFFSAA
1772
NVNSxVF
1078
VPAxNxxP
110
VAVCAxSA
443
SASSVxVR
286
FSxPKF
643
VxCFNxP
140
NRSVRxC
114
SSFNKxR
230
SRNRFAFR
765
SRCSVxR
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Maximum
Score
0.043
0.136
0.074
0.018
0.080
0.085
0.127
0.073
0.088
0.083
0.132
0.098
0.162
0.072
0.037
0.186
0.130
0.016
0.124
0.098
0.216
0.059
0.102
0.088
0.074
0.046
0.096

Example
Peptide
GVGRCYP
QGRAGNAS
PVWQGRVP
VGATTGLQ
VTRLPAPR
RNSSRRDS
RMAHCRAP
SSGMRFSV
ERERLGHE
LQPPRSV
YLENLWML
SERYTVLL
GFQLGGGL
EEGTLRKG
YSHAYSS
SSEGLRAL
CGATFWCK
WVVTNLED
IPGHDDIP
ATSGCVGV
TGTSLCLR
SSWKPESW
VCCFETP
AERSVRGC
MTSWDKYR
TRERFGWR
RMMSCRTN

Table 3-15. Summary of motif selection analysis performed using ChemGPS-9D
amino acid substation matrix and simple score ranking for all patient tissues
recovered.

Tissue
Adrenal Gland
Aorta
Bladder
Bone Marrow
Bowel
Brain
Coronary Artery
Duodenum
Duramater
Esophagus
Fat
Gallbladder
Heart
Kidney
Liver
Liver Tumor
Lung
Lymph Node
Muscle
Pancreas
Prostate
Skin
Spleen
Stomach
Testis
Thyroid
Yellow Bone Marrow

ChemGPS-9D Simple Score
Highest
Unique Peptides Scored Motif
116
VPDPNV
74
RSFSFxN
108
VVRVDFR
4006
SFVSFA
161
FVVVPxA
163
PxDAADN
142
NFFVSVA
148
FxPSFC
164
VxDACAS
165
VxKxHxxH
233
VFxxSNN
221
VKASRxN
176
VVRxDNxS
212
VACPCNR
657
VAVRCC
176
HSxxRKxA
175
SSFPRxD
584
HxDVxSxD
87
VFKVAS
139
HVFxSVA
108
DSFFAAA
218
VxACCDV
313
AxxFxACA
281
VxPxVNAV
129
RVPRxPxA
208
DRDxxFFD
274
RxAKxAxN
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Maximum
Score
0.295
0.475
0.480
0.099
0.410
0.398
0.579
0.453
0.435
0.440
0.417
0.413
0.538
0.297
0.249
0.531
0.460
0.156
0.348
0.453
0.616
0.418
0.407
0.512
0.361
0.330
0.295

Example
Peptide
VPDPQIS
QMFTWSR
VMRVEYRC
TAFSVFS
WVMMPLGR
PREGAEQ
QWYVSVGE
FGPTFCL
VVCDGCAT
VVKLHPRH
VYTYSQQM
QVRSGKV
SSNDPRLL
MGCPCQR
VGLRCCL
ATKRWPTH
EARPWST
HSDLRTWE
TGLKFLRQ
AVSLFVH
DSYWGAG
VDCCAIV
ARLWDGCG
LTPAVQAV
GSPSRPLR
EYYAGERE
RLAKVGLN

Table 3-16. Summary of motif selection analysis performed using ChemGPS-9D
amino acid substation matrix and combination score ranking for all patient tissues
recovered.

Tissue
Adrenal Gland
Aorta
Bladder
Bone Marrow
Bowel
Brain
Coronary Artery
Duodenum
Duramater
Esophagus
Fat
Gallbladder
Heart
Kidney
Liver
Liver Tumor
Lung
Lymph Node
Muscle
Pancreas
Prostate
Skin
Spleen
Stomach
Testis
Thyroid
Yellow Bone Marrow

ChemGPS-9D Combo Score
Highest
Unique Peptides Scored Motif
168
PFCRAVA
136
VCVVSAV
108
PVxANFVP
2135
SFVSFA
321
RHRxFxF
148
SDRRSSxR
110
VAHCRAP
122
VSFRVAxS
195
DRDRxAHD
90
VRNAxxAP
493
SHxFFN
199
VVVxFRDS
174
VAxAVNFA
229
DDxSxRKA
946
VFVxxxAK
998
RxFxVxNA
82
VxRRxCR
1599
RDKVxD
912
RSFxNRP
91
VAVCAxSA
344
VSxFVDF
941
PVxRSH
655
VxCFDxP
106
SHVxxSK
82
SSFDKxR
175
RRVVxSN
607
RxAKxAxN
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Maximum
Score
0.043
0.120
0.074
0.017
0.085
0.083
0.127
0.073
0.093
0.078
0.118
0.098
0.183
0.072
0.029
0.182
0.139
0.021
0.114
0.098
0.231
0.067
0.102
0.094
0.074
0.055
0.080

Example
Peptide
GVGRCYP
VCMLTAV
PVWQGRVP
TAFSVFS
RHRAFLW
SDRRTSLR
RMAHCRAP
SSGMRFSV
ERERLGHE
PGAPAQRL
ISHWFWQ
SERYTVLL
GFQLGGGL
EEGTLRKG
KAGTGVFL
GNQVVFRR
VYRRSCR
REKLSEL
SRTWVNRP
ATSGCVGV
SWDMFDSI
RHTRILP
VCCFETP
LKTGTLHS
MTSWDKYR
ANTVLMRR
RLAKVGLN

Table 3-17. Peptides clustering to top 100 motifs in all 10 analyses.
Tissue

Peptides- All Scores

Adrenal Gland

LRKWNVRW

Aorta

KGATTGHG, KGATTGHV

Bladder

GRYGNSSE

Bowel

EVAAGSSS

Brain

GGSRSLRL

Duodenum

GVIGGITR

Duramater

SAGTADTM, SAGTAGTM

Esophagus

HVGHLKRL, PEHWSAKG, PEHWSAKR, PEHWSAKV

Fat

MWHGTQQR

Gallbladder

DTRETNTG

Kidney

QDRLASAR, QDRLASTR, QDRLASVR

Liver Tumor

SSEGLRAL, TTRKFSDT

Lymph Node

EVSLADRH, EVSLVDRH

Prostate

DSYWAAG, DSYWGAG

Spleen

GTPWTGCG, RLQSTGTN

Thyroid

DRIGSYFD, EYYAGERE, EYYVGERE, RRLVITNV

Yellow Bone Marrow

DALDGFPK, GVNGQKHW, HAWSKSTV, HVWSKSTV
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Table 3-18.
18. Peptides clustering to top 100 motifs in all analyses using simple score
motif ranking.
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Table 3-19.
19. Peptides clustering to top 100 motifs in all analyses using combination
score motif ranking.
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cross-referenced
referenced with biologically
Table 3-20. Top motifs from liver tumor analysis cross
relevant peptides. PEPBANK database used.
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justification for selection is also included. For example, the ligand, amphiregulin,
contains a region, CQQEYFGERC, that shares sequence similarity with a peptide
clustered to a top motif in liver tumor. The di-sulfide bonds between the cysteines in this
region have been shown to be important in interacting with epidermal growth factor
receptor (EGFR), commonly upregulated on the surface of tumor cells [84, 85]. These
data suggest that the selected peptide may bind to EGFR and this interaction may imitate
an endogenous phenomenon specific to tumor cells, leading to further confidence for
tumor targeting strategies. Furthermore, the sequence CYIQNC/CYFQNC also mimics a
top motif selected in HCC tissue, and contains a biologically active site found in the
hormones oxytocin and vasopressin and may also form disulfide bonds important for
receptor ligation [86]. Using this type of information, additional peptides mimicking the
binding site for proteins important for biological function can be identified.
To determine the significance of our candidate peptides with respect to the
multidimensional analysis, we examined the sequence homology between SGVGAASL
and peptides clustering to top 1,000 motifs selected in data recovered from liver tumor
tissue. Encouragingly, 4 and 5 consecutive amino acid matches were found in each
analysis (Table 3-21a). Peptides and their respective motifs found to match 5 consecutive
amino acids to peptide SGVGAASL are shown in Table 3-21b. These data suggest that
the peptide SGVGAASL is indeed significant in liver tumor tissue as validated by
multiple selection algorithms. Characterization of this peptide and its corresponding
receptor warrants further consideration.
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Table 3-21. Peptide SGVGAASL clustering to top 100 motifs in liver tumor tissue. a)
Summary of peptides containing four or five amino acid matches to peptide
SGVGAASL. b) Peptides clustering to top 100 motifs in liver tissue containing five
amino acid matches to peptide SGVGAASL. Motifs from which the peptides clustered
are also shown.
a.
Amino acid
substitution
matrix
BLOSUM62
2D
ROCS
ChemGPS-4D
ChemGPS-9D

Peptides matching
4 amino acids
34
72
3
48
39

Peptides matching
5 amino acids
2
8
0
1
1

b.

BLOSUM62
SAAGLRAV
SAAGVIWW
Peptides
matching
5 amino
acids

Motifs
containing
matching
peptides

SxxGLRAL
FxLLGAA

Amino acid substitution matrix
2D
ChemGPS-4D
RHESGLAG
WRQSAGGL
KGPGVGSR
GAAVGMFR
KGAALGFR
RAGGLAGR
RGAGVALR
WRQSAGGL
QMTLAAGD
RNDxxxAA
FRNSAxA
RxALxAAR
FRNSAxA
NLxLxAxD
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ChemGPS-9D
WRQSAGGL

FRNSAxA

3.3

Peptide SGVGAASL mediated targeting of liver tumor cells
To validate the specificity of the SGVGAASL peptide mediated targeting, peptide

binding assays were performed to investigate selective phage binding to the surface of
HCC cells. For HEPG2 cells, phage displaying the SGVGAASL peptide bound to the
surface of cells ~3 fold more than control insertless phage (p < 0.05, Fig. 3-12a).
However, for SNU449 cells there was no difference in the number of targeted phage
binding when compared to insertless phage. These results suggest that the cell surface
receptor responsible for peptide binding is unique to certain subtypes of HCC. This
hypothesis was further examined in Chapter 3.5.
We next performed an internalization assay to determine a functional interaction
between HCC cells and SGVGAASL-displaying phage. Following 24 hr incubation,
peptide mediate phage internalization into HEPG2 and SNU449 cells was detected by
immunofluorescence of permeabilized cells. After incubation with SGVGAASLdisplaying phage, HEPG2 cells internalized phage particles while incubation with
insertless control phage did not result in internalization of phage (Fig. 3-12b, top panel).
In accordance with previous experiments, SNU449 cells did not internalize SGVGAASLdisplaying phage or insertless control phage (Fig 3-12b, bottom panel).
We next performed a pilot in vivo experiment to determine if SGVGAASL can
mediate peptide targeting in preclinical models of HCC. Orthotopic tumors were grown
in the liver of mice using HEP3B HCC cells. When tumors reached an appropriate size,
SGVGAASL peptide labeled with IRDye 800CW Infrared Dye was injected
intravenously at increasing doses. Images were acquired by a Pearl Impulse Small
Animal Imaging System (LI-COR) after 72 hr of circulation. Dye signal measured in the

89

a.

b.

Fig. 3-12. SGVGAASL-peptide
peptide displaying phage binding and internalization in
HCC cells. a) Phage binding to surface of HCC cells. Relative binding of SGVGAASLSGVGAASL
displaying phage to HCC cell lines SNU449 and HEPG2 was assessed by the BRASIL
assay. Insertless phage was used as negative control. b) Cell internalization of
SGVGAAS -displaying
displaying phage
phage.. HEPG2 and SNU449 cells were incubated with
SGVGAASL-displaying
displaying phage for 24 hr (left panels). Insertless phage were used as
control (right panels). Phage particles (red dots) were detected by labeling with a Cy-3
Cy
conjugated antibody. Cell nuclei were sta
stained with DAPI (blue). *p < 0.05.
90

tumor was higher than in the control organ (brain), and the signal increased in a dose
dependent manner (Fig. 3-13). While these results are preliminary and require more
extensive study, they are promising towards the development of the SGVGAASL peptide
for targeted drug delivery or imaging modalities.

3.4

Peptide SGVGAASL endogenous receptor purification
Peptide affinity was used to isolate proteins binding to SGVGAASL with the goal

of identifying an endogenous tumor-specific receptor for this peptide. Protein extract was
incubated with peptide affixed to long arm amine terminated magnetic beads and
fractionated after washing. Fractionated proteins were incubated with phage displaying
the SGVGAASL peptide and phage binding was investigated. SGVGAASL–displaying
phage bound to fractions purified with SGVGAASL peptide incubated with liver tumor
protein in higher quantities compared to fractions purified from normal liver protein (Fig.
3-14a), while insertless phage did not bind to either fraction. These data suggest that the
receptor for the peptide SGVGAASL is either present in higher quantities or in a more
preferential binding conformation in purified protein from liver tumor than normal liver
tissue.
Fractionated proteins were next resolved by 2D gel electrophoresis and compared
to control fractions (Fig. 3-14b). Unique bands were excised from the gels, digested with
trypsin and submitted for LC-MS/MS based protein analysis. Mass spectrometric peptide
mapping analysis revealed signatures that matched the protein giantin, a 376kDa golgi
membrane protein that has no previously described function in cancer.
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Fig. 3-13.
13. SGVGAASL peptide homing to orthotopic HCC tumors in mice. Animals
were intravenously injected with 10 µg, 15 µg, 30 µg, or 50 µg of SGVGAASL peptide
labeled with IRDye 800CW infrared dye. Signal in tumor and brain tissue was measured
after 72 hr of circulation time using a Pearl Impulse Small Animal Imaging System (LI(LI
COR)
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a.

b.

Fig. 3-14.
14. Receptor purification for SGVGAASL peptide. a) Binding of proteins
eluted by peptide affinity chromatography to phage displaying the peptide SGVGAASL.
In the eluted fraction, a positive
tive protein
protein-peptide
peptide interaction was measured when
compared to binding with insertless phage. b) 22-dimensional
dimensional gel electrophoresis was
performed on proteins purified by peptide affinity chromatography. Two protein sources
were used for the purification: no
normal
rmal human tissue (left) and human liver tumor tissue
(right). Proteins from normal tissue were purified by peptide affinity chromatography as a
control (left panel). Proteins purified from liver tumor tissue are shown in the right panel.
Circled bands weree exclusively present in fractions purified from liver tumor tissue.
These bands were excised and sent to mass spec for identification.
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To confirm the binding interaction between giantin and the SGVGAASL peptide,
we performed binding assays using SGVGAASL- displaying phage with proteins
immunoprecipitated from liver tumor protein extract with an anti-giantin antibody. This
allowed for isolation of the receptor in a structural confirmation that is most
representative to that found in liver tumor. Furthermore, recombinant giantin was not
commercially available and immunocapture techniques represented the best option to
isolate it. Phage displaying the SGVGAASL peptide were incubated with
immunocaptured giantin and bound phage were quantified using real-time PCR (Fig. 315). As expected, targeted phage bound to immunocaptured giantin in higher quantities
compared to insertless phage. Neither phage bound to a control coating of BSA. These
data suggest that phage displaying the SGVGAASL peptide bind to giantin in vitro.

3.5

Giantin expression in patient tissue
After validating the interaction between the peptide SGVGAASL and giantin, we

next examined the expression of this protein in patient samples. Previously, giantin has
been described as a Golgi membrane protein in the literature and expression has not been
linked to cancer. Here, we found a distinct expression pattern in liver tumor samples
obtained from patient 6 (Fig. 3-16). Expression of giantin was significantly upregulated
in tumor tissue compared to normal liver with significant vascular localization. IHC
giantin staining showed moderate to strong membranous staining in the endothelium,
however, staining in malignant cells was negative. This finding was unexpected given
that in vitro studies using HCC cell lines have shown that giantin is present on the tumor
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Fig. 3-15. SGVGAASL-peptide
peptide displaying phage binding to immunocaptured
receptors. Antibodies against giantin as well as BSA were used to immunocapture
proteins extracted from human liver tumor tissue. SGVGAASL
SGVGAASL-displaying
displaying phage were
incubated with immunocaptured proteins and following washing, were quantified using
real-time PCR. Insertless
less phage was used as a negative control and showed binding at
background levels. **p < 0.01.
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Fig. 3-16.
16. Giantin staining in HCC and normal liver tissue sections obtained from
patient 6.
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cell membrane and SGVGAASL peptide binds to the surface of HCC cells (Chapter
3.6).
Due to the unique expression pattern for giantin observed in a subset of HCC
samples, we next explored the expression of this protein in a large cohort of HCC patient
samples including whole slide tissue sections of patient HCC tissue as well as a HCC
TMA comprised of 142 samples. A similar study was designed to evaluate expression of
giantin in several normal tissues including liver, prostate, testis, heart, and placenta and
other cancers including prostate, breast, colon, non-small cell lung, and ovarian cancer to
provide a comprehensive evaluation of giantin as a molecular marker of HCC and
potentially other cancers.

3.5.1

Giantin expression in HCC patient samples

We expanded our tissue study to include slides from 30 patients with HCC
provided by a collaborator, Dr. Steven Curley (Department of Surgical Oncology,
University of M.D. Anderson Cancer Center, present address: Department of Surgery,
Baylor College of Medicine). Of the 30 patient samples, 12 samples (40%) exhibited a
similar vascular membrane expression pattern of giantin as observed in patient 6 (Fig. 317). Of the remaining samples, 14/30 or 47% exhibited increased cytoplasmic expression
of giantin, and 4/30 or 13% of samples exhibited very low overall giantin expression.
These data suggest that the vascular expression pattern may not be restricted to patient 6,
but may be observed in a unique subset of patients with HCC. This observation was
further confirmed in a small cohort of HCC samples obtained commercially (N=7). Each
HCC tumor sample was provided with a sample of adjacent healthy liver tissue. When
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Fig. 3-17.
17. Giantin staining in archival tissue specimens from HCC patients.
Immunohistochemistry was performed on tissue sections using an anti
anti-giantin
giantin antibody.
Vascular staining was observed in 12/30 (40%) of samples (top row). Cytoplasmic
staining was observed in 14/30 (47%) samples (middle row). Negative staining for
giantin was observed in 4/30 (13%) samples (bottom row).
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giantin localization was examined, we observed a unique vascular cell surface expression
pattern in a subset of HCC patients (4 out of 7 samples, 57%) while adjacent normal
tissue showed no vascular membranous staining (Fig. 3-18).
Next, three full tissue specimens each including HCC tumor tissue, adjacent
benign tissue, and vessels were examined. Malignant cells in HCC showed only weak,
limited nuclear and cytoplasmic staining (Fig. 3-19a). Positive staining was observed in
the endothelium lining the capillaries (sinusoids) within both tumor and benign liver
parenchyma. Staining was localized to the basal membranes and sometimes to the
extracellular space adjacent to malignant cells and again appeared to be associated with
vasculature (Fig. 3-19a). In our previous studies, endothelial cells demonstrated
particularly intense staining in HCC compared to in normal liver tissue. However, in the
samples used in this study, there was no association of the intensity or prevalence of
endothelial staining in malignant areas compared to surrounding benign tissues (Fig. 319a). Of note, positive giantin expression in the vasculature of benign tissue may be
affected by the associated disease processes in the benign liver tissue adjacent to tumors.
Specifically, two of the samples displayed cirrhosis in benign liver tissue, the major risk
factor for HCC, and the third showed fatty changes (steatosis) (Fig. 3-19b).

3.5.2

Giantin expression in a HCC tissue microarray

Large scale analysis of giantin expression in patient tissue was performed by
analysis of a HCC TMA. The TMA composed of liver tumor (N=131), normal liver
(N=4), and inflammatory liver (N=6) patient samples was acquired from BioChain and
stained for giantin expression. Staining intensity was recorded on a scale of 0-4
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Fig. 3-18.
18. Giantin protein expression in HCC tissue specimens and adjacent normal
liver tissue. Immunohistochemistry was performed on commercially obtained HCC
samples and adjacent normal liver tissue using an anti-giantin antibody.
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Fig. 3-19.
19. Giantin staining in human HCC cancer and benign liver tissue.
Immunohistochemistry was performed using an anti
anti-giantin
giantin antibody. a) Giantin staining
in malignant cells and vessels (left) and hep
hepatocytes
atocytes and vessels (right). b) Giantin
staining in additional tissue types including liver parenchyma and cirrhotic liver.
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(0=negative, 1=minimal, 2=faint, 3=moderate, 4=strong). Of the 131 liver tumor samples,
86 (65%) exhibited minimal to strong staining of giantin in the tumor vasculature. Of the
six inflammatory liver tissues, all (100%) exhibited minimal to faint staining of giantin in
the vasculature. Of the four normal liver samples, two (50%) exhibited minimal to faint
staining of giantin in the vasculature. Carry-over controls of full tissue liver samples
(patient 6 HCC tissue sample and benign liver tissue sample) showed staining that was
similar to previous studies, in which the malignant sample showed positive staining in
vasculature that was not apparent in the normal sample.
Analysis of TMA staining results determined that there was an overall higher
expression of giantin in the tumor vasculature when compared to normal samples (Fig. 320b). 20% of HCC samples (N=23) exhibited moderate to strong staining in the
endothelium compared to only faint to negative staining in normal endothelium (N=4).
There was no difference in giantin expression in malignant cells in HCC samples when
examined by tumor grade (Fig. 3-21a); however, when examined by tumor stage,
malignant cells in HCC exhibited higher expression of giantin in more advanced stage
tumors (T4) when compared to all other stages (T1-T3) (Fig. 3-21c). In HCC-associated
vasculature, giantin expression was moderate to strong in high and low grade (I, I-II, and
III) tumors but lower in middle grade tumors (II and II-III) (Fig. 3-21b). This correlation
was also observed in HCC associated vasculature when examined by tumor stage. Stage
T1 and T4 tumors exhibited higher vascular expression of giantin compared to stage T2
and T3 tumors (Fig. 3-21d). In both malignant cells and vascular cells, there was no
correlation between giantin expression and patient age (Fig. 3-21e-f).
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Fig. 3-20. Giantin staining
aining in normal and diseased human liver tissue. a) Scores for
giantin staining in malignant cells (cholangiocarcinoma and HCC), or normal hepatocytes
(normal and inflammatory tissue). b) Scores for giantin staining in vascular cells found in
diseased and normal liver tissue.
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Fig. 3-21.
21. Giantin staining in HCC tissue by patient and tumor characteristics.
Scores for giantin staining in malignant cells (a), or vascular cells (b) by tumor grade.
Scores for giantin staining in malignant cells (c), or vascu
vascular
lar cells (d) by tumor stage.
Scores for giantin staining in malignant cells (e), or vascular cells (f) by patient age.
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Given the diversity and semi-qualitative nature of histological metrics coupled
with the complications of biomarker scarcity associated with TMAs, inferences about
statistical significance are not necessarily evident especially when scored a single time
[87, 88]. However, when a subpopulation of samples defined by positive (nonzero)
vascular giantin expression were examined, there was an increase in staining in HCC
samples when compared to inflammatory tissue as well as normal liver tissue that was
determined to be statistically significant by chi-squared testing (p < 0.05, Fig. 3-22a).
Likewise, when HCC samples with positive expression of giantin in malignant cells were
examined, vascular staining was increased in positive malignant cells. Stronger malignant
cell staining correlated with stronger endothelial cell staining (Fig. 3-22b).
For samples of inflammatory liver (N=6), there was no difference in giantin
antibody staining compared to normal hepatocytes and malignant tissue (Fig. 3-20a).
However, there was an increase in vascular staining for giantin in endothelial cells
associated with inflammatory liver tissue compared to endothelial cells associated with
normal liver (Fig. 3-20b).
Several samples of cholangiocarcinoma (N=14, bile duct carcinoma) were
included, and appeared to show more intense and consistent staining in malignant cells
than the HCC samples (Fig. 3-20a); however, vascular staining of giantin in
cholangiocarcinoma did not differ from vascular staining in HCC samples (Fig. 3-20b). A
single sample (N=1) of metastatic HCC colon adenocarcinoma exhibited moderate to
strong malignant cell staining (score=3.5) as well as faint vascular cell staining (score=2).
For the TMA, all of the cases were in duplicate, and the staining was very consistent
between cores from the same samples.
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Fig. 3-22.
22. Giantin staining in HCC vasculature. a) Scores for giantin staining in
endothelial cells in HCC, inflammatory, and normal liver tissue. b) Scores for giantin
staining in endothelial cells by malignant cell score. *p < 0.05, Χ2 test.
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3.5.3

Giantin expression in normal patient tissue

Giantin staining was examined in a panel of normal tissues to establish baseline
expression. In a sample of normal liver obtained from a 60-year-old female, giantin
antibody showed faint membranous staining in sinusoidal endothelium and minimal
staining in hepatocytes. Strong staining was present in intravascular leukocytes and
minimal staining was occasionally present in bile ducts and vascular smooth muscle (Fig.
3-23a). In a sample of normal prostate obtained at surgery from a 49-year-old male,
giantin antibody showed faint to moderate staining in glandular epithelium while stroma
was negative (Fig. 3-23b). In a sample of normal testis obtained at surgery from a 37year-old male, giantin antibody showed moderate to strong cytoplasmic, nuclear, and
membranous staining in seminiferous precursors, and minimal cytoplasmic and nuclear
staining in Leydig cells (Fig. 3-23c). In a sample of normal heart obtained at autopsy
from a 24-year-old female, giantin antibody showed faint staining in endothelium, but
cardiomyocytes were negative (Fig. 3-23d). In a sample of normal placenta obtained at
surgery from a 25-year-old female, giantin expression was absent (Fig. 3-23e).

3.5.4

Giantin expression in additional cancers

Giantin expression was also examined in five additional tumor types including
prostate, breast, colon, non-small cell lung, and ovarian cancer. Whole slide specimens
containing tumor tissue, benign tissue, and vessels were examined. Prostate carcinomas
showed the most prominent expression of giantin, with intense cytoplasmic staining in
malignant cells that was stronger than staining in surrounding benign prostate epithelium
(Fig. 3-24a-c). In one sample, staining was more prominent in higher grade malignant
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Fig. 3-23.
23. Giantin staining in normal human tissue. Immunohistochemistry was
performed on tissues from a) liver, b) prostate, c) testis, d) heart, and e) placenta using an
anti-giantin antibody.
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Fig. 3-24.
24. Giantin staining in human prostate cancer and normal prostate tissue.
Immunohistochemistry was performed using an anti
anti-giantin
giantin antibody. a) Giantin staining
in malignant glands (top left), normal glands (top right), tumor vessel (bottom left), and
normal vessel (bottom right). b) Giantin sstaining
taining in grade 4 and grade 3 prostate cancer,
benign hyperplastic glands, and normal glands. c) Giantin staining in malignant glands,
intraepithelial neoplasia, and normal glands.
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tissue, compared to lower grade tumor and benign hyperplastic glands (Fig. 3-24b).
Another sample showed intense staining in prostatic intraepithelial neoplasia, similar to
the associated invasive tumor and significantly stronger than staining in benign glands
(Fig. 3-24c). Endothelium exhibited moderate membranous and extracellular staining in
larger vessels, but showed only minimal to faint staining in capillaries. There was no
relationship to intensity of staining in endothelium when compared to proximity to tumor
(Fig. 3-24a).
In breast cancers, malignant cells displayed frequent intense cytoplasmic staining
as well as weaker membranous staining (Fig. 3-25a). Staining in the malignant cells was
more uniform and generally stronger than staining in benign ducts and lobules (Fig. 325a). One sample showed more prominent staining in the myoepithelial cell layer of
benign ducts and lobules compared to the inner glandular layer lining glandular lumen
(Fig. 3-25a top), whereas a second sample showed the opposite pattern and was negative
in myoepithelial cells but positive in the luminal glandular epithelium (Fig. 3-25a
bottom). Vascular staining was not observed in breast cancer or adjacent benign tissue
(Fig. 3-25b).
Colon cancers showed positive staining that was similar to the staining observed
in benign glandular epithelium in two samples (Fig. 3-26a), and variable in a third, with
areas of intense staining and large areas that were completely negative (Fig. 3-26b).
There was only minimal staining in vasculature and no differential staining with respect
to proximity of tumor versus benign tissue (Fig. 3-26c).
NSCLC exhibited positive staining that was similar to staining in benign
respiratory epithelium but stronger than staining in benign pneumocytes in two of three
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Fig. 3-25.
25. Giantin staining in human breast cancer and normal breast tissue.
Immunohistochemistry was performed using an anti
anti-giantin
giantin antibody. a) Giantin staining
in malignant cells (left) and normal cells (right). b) Giantin staining in tumor vessels
(left) and normal capillaries (right).
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Fig. 3-26. Giantin staining in human colon cancer and normal colon tissue.
Immunohistochemistry was performed using an anti
anti-giantin
giantin antibody. a) Giantin staining
in malignant glands (left) and normal mucosa (right) for two patients. b) Giantin staining
in malignant glands (left)
left) and normal mucosa (right) for an additional patient. c) Giantin
expression in tumor vessels (left) and normal vessels (right).
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samples (Fig. 3-27a). The third sample showed strong staining in malignant cells, but
only minimal staining in benign respiratory epithelium (Fig. 3-27b top). In this sample,
there was also an increased association of staining in tumor vessels compared to benign
vessels (Fig. 3-27b bottom). Only minimal staining was present in vasculature for the
remaining samples (example shown in Fig. 3-27c). Additional cell types in lung that
showed positive staining included benign alveolar macrophages, reactive type II
pneumocytes, and neutrophils (Fig. 3-27d).
Ovarian carcinomas displayed relatively prominent staining in malignant cells,
with mostly cytoplasmic staining (Fig. 3-28a). Only minimal staining was present in
vasculature and there was no particular association with vascular staining in the ovarian
carcinomas (Fig. 3-28b).
Based on these results, giantin expression appeared to vary not only by cancer
type but in some cases, by patient. While higher overall expression was observed in
several cancer types when compared to adjacent normal tissue, vascular expression of
giantin was found to be unique to a subset of HCC patients indicating that peptide
mediated targeting would be most beneficial in this setting.

3.6

Giantin cell surface expression in HCC and endothelial cells
We next examined the expression of giantin on the surface of HCC cells. Protein

from each cell line was fractionated and giantin expression was measured in the plasma
membrane fraction by Western blot analysis. In HEP3B cells, giantin expression was
found in the plasma membrane fraction whereas control proteins MEK1/2 (cytoplasm)
and Golgi 58K (Golgi complex) were not, thus confirming successful fractionation
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Fig. 3-27.
27. Giantin staining in human non
non-small
small cell lung cancer (NSCLC) cancer
and normal lung tissue. Immunohistochemistry was performed using an anti-giantin
anti
antibody. a) Giantin staining in malignant cells (left) and normal lung epithelium (right).
b) In an additional patient, differential giantin staining in malignant cells (top left) and
normal airway cells (top right) as well as tumor vessels (bottom left) and normal vessels
(bottom right). c) Giantin expression in tumor vessels (left) and normal vessels (right) in
a patient with NSCLC. d) Giantin expression in additional cell types inclu
including
ding alveolar
macrophages, reactive type II pneumocytes and neutrophils.
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Fig. 3-28.
28. Giantin staining in human ovarian cancer and normal ovarian tissue.
Immunohistochemistry was performed using an anti
anti-giantin
giantin antibody. a) Giantin staining
in malignant cells for three patients. b) Giantin staining in tumor vessels (left) and normal
vessels (right).
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enrichment (Fig. 3-29a). In SNU449 cells, giantin membrane expression was found to be
lower than with HEP3B cells.
The plasma membrane fraction isolated from HEP3B cells was used to examine
phage binding. Giantin was immunocaptured from plasma membrane fractions and
incubated with phage (displaying the SGVGAASL peptide or no peptide as a negative
control). Bound phage were quantified by ELISA using an HRP-labeled anti-phage
antibody. For the plasma membrane fraction, SGVGAASL- peptide displaying phage
bound to proteins captured by the giantin antibody but not to proteins captured by
MEK1/2 (intracellular marker) or BSA (Fig. 3-29b). These results confirm that giantin
was present in the plasma membrane fraction and that the binding event between phage
displaying the peptide SGVGAASL and giantin is not dependent on subcellular
localization.
Cell surface localization of giantin was confirmed by FACS analysis on live cells.
HCC cell lines, HEP3B, HEPG2, and SNU449 were each examined. As controls,
expression of intracellular proteins MEK1/2, Golgi membrane protein 58K, and nuclear
protein Orc2 were also examined. For live cells, giantin was detectable on the surface of
HEP3B and HEPG2 cells but not on SNU449 cells while intracellular, Golgi, and nuclear
markers were each negative (Fig. 3-30a). When the cell membrane was permeabilized
and intracellular proteins were included in the analysis, each marker was positive and
giantin staining increased as expected. Furthermore, when giantin expression was
examined in HDMECs, cell surface expression was also slightly positive, supporting the
vascular staining pattern observed in histology (Fig. 3-30b). Interestingly, when
HDMECs were activated with VEGF which is known to stimulate endothelial cell
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a.

b.

Fig. 3-29.
29. SGVGAASL displaying phage binding to giantin purified from plasma
membrane protein fraction of HCC cells. a) Western blot analysis was performed on
total protein extract as well as plasma membrane proteins isolated from the HEP3B and
SNU449 cell lines. Expression of giantin as well as intracellular proteins MEK1/2 and
58K were examined. b) Giantin and MEK1/2 antibodies were isolated in wells and
incubated with plasma membrane protein fraction isolated from the HEP3B cell line.
Wells were coated with BSA as a negative control. Immunocaptured proteins were
incubated with SGVGAASL displaying phage or insertless pphage
hage overnight, washed, and
detected using an HRP conjugated anti
anti-phage antibody. **p < 0.01.
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Fig. 3-30.
30. Cell surface expression of giantin on HCC cells and endothelial cells. a)
FACS analysis was performed on live and permeabilized HCC cell lines HEP3B,
HEP3
HEPG2, and SNU449 using an antibody against giantin (bottom panels). As controls,
FACS analysis using antibodies against a cytoplasmic protein (MEK1/2), a nuclear
protein (Orc2), and a Golgi organelle protein (58K) was also performed. Results for
controll experiments are shown in HEP3B cells (top panels) but were similar in all cell
lines. b) FACS analysis was performed on live and permeabilized HDMEC endothelial
cells using an antibody against giantin. Prior to FACS analysis, cells were starved in
media not containing growth factors or FBS for 24 hr then activated with VEGF for 4 hr.
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proliferation, migration, sprouting, and permeability, the expression of giantin on the
surface increased. These results coupled with histological studies and Western blot
analysis on fractionated proteins confirm in a live cell setting that giantin is expressed on
the cell surface of HCC cell lines and endothelial cells.

3.7

Giantin function in HCC cells
In order to examine the function of giantin in cancer cells, we constructed shRNA

lentivirus targeting giantin mRNA. HEP3B cells were infected with targeted virus and,
after 48 hr, expression of giantin protein was eliminated (Fig. 3-31a). Interestingly, the
cleaved caspase-3 marker for apoptosis was not positive in any cells indicating that
giantin silencing does not lead to apoptosis. The proliferation marker, Ki67, was not
positive in giantin depleted cells, but positive in cells infected with untargeted virus or
non-infected cells. The adhesion marker, E-cadherin, was decreased in giantin
knockdown cells, suggesting a role for giantin in cell adhesion and proliferation
mechanisms. Furthermore, 72 hr after viral infection, cell morphology was examined. In
giantin depleted cells, cell morphology drastically changed when compared to noninfected cells and cells infected with untargeted constructs (Fig. 3-31b). Loss of adhesion
and a decrease in proliferation were again observed. Furthermore, when giantin depleted
HEP3B cells were grown on a plate that measures changes in electric potential in real
time (Roche xCELLigence), an overall lag in cell attachment after 8 hr and decrease in
proliferation after 48 hr when compared to untreated cells were observed (Fig. 3-32a,b).
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Fig. 3-31.
31. Giantin knockdown in HEP3B cells. a. Protein expression in giantin depleted
cells. Cells were incubated with shRNA targeting giantin mRNA or control non-targeted
non
virus for 24 hr, media was refreshed with media containing puromycin antibiotic (5
µg/mL).
g/mL). Cells were harvested 24 hr after selecti
selection
on and protein was extracted for Western
blot analysis. b. Phenotypic analysis of giantin knockdown in HEP3B cells. Cells were
incubated with shRNA targeting giantin mRNA or control non
non-targeted
targeted virus for 24 hr,
media was refreshed with media containing pu
puromycin antibiotic (5 µg/mL).
g/mL). Light field
images of cells were taken 24 hr after selection.
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a.

b.

Fig. 3-32.
32. Cell adhesion and proliferation kinetics following shRNA
shRNA-mediated
mediated
depletion of giantin in HEP3B cells. Cells were incubated with shRNA targeting giantin
mRNA for 24 hr, media was refreshed with media containing puromycin antibiotic (5
µg/mL).
g/mL). Cells were harvested 48 hr after selection and plated on 96 well tissue culture EE
4
Plates (Roche) at 10 cells per well. The Roche xCELLigence machine which measures
electrical impedance in real time as cells attached and grow on E
E-plates
plates was programmed
to take measurements every minute for 48 hrs where a) represents data recorded from 0-8
0
hr and b) represents
esents all data recorded.

121

CHAPTER 4: DISCUSSION

The high-throughput, bacteria-free phage display approach described in this work
involves the implementation of next-generation sequencing to facilitate synchronous
selection in multiple human tissues in a single screening round. This methodology allows
for screenings to be performed 1,000 x faster and 250 x cheaper while recovering an
increase of 2 to 4 orders of magnitude in the number of sequences. Approximately 1.5
million peptides sequences were recovered from a phage display screen in a patient with
primary HCC and RCC utilizing the Roche 454 sequencing platform. Normal as well as
diseased tissues were examined to build a comprehensive overview of molecular
heterogeneity in the human vasculature.
In order to analyze these large datasets, we developed a relational database with
the ability to extract amino acid sequences from raw DNA sequencing data recovered
from phage isolated in each tissue, query for peptide sequences and calculate saturation
of recovered data in each tissue. This tool has been designed to be accessible online as a
valuable academic resource for groups studying vascular markers present in both normal
and disease physiology. Likewise, we have developed an advanced bioinformatic
workflow to select for significant peptide motifs in tissues of interest. By considering the
multidimensional characteristics associated with short peptides including amino acid
sequence, physiochemical properties, shape/pharmacophoric properties, and “druglike”
properties, panels of tissue-specific motifs were identified in 27 human tissues, including
HCC. Many peptides identified through these analyses overlapped, further increasing our
confidence in their specificity to target organs.
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Furthermore, peptides selected from HCC tissues were cross-referenced with the
PepBank database (a compilation of biologically relevant peptide sequences made
publically available online). A preliminary analysis uncovered 14 endogenous ligands
involved in cancer that matched to top peptides we identified in HCC. Addition of this
validation step in the bioinformatics workflow would allow for more informed
hypotheses of potential receptor/ligand complexes uncovered in phage display screens as
well as aid in the selection of peptide ligands that have functional roles in disease
development and progression.
Each selectively identified peptide represents a potential targeting ligand for
delivery of drugs or imaging agents in humans. As future studies, it would be interesting
to examine these data sets in the context of ligand heterogeneity between human and nonhuman primates. Recently, a colony of rhesus macaques was found to carry germline
mutations that cause the equivalent of the human genetic disease, Lynch syndrome, also
known as Hereditary Non-Polyposis Colon Cancer (HNPCC) where mutations in the
DNA mismatch repair pathway leads to an increased risk of cancer. A phage display
screen was performed in a rhesus with HNPCC and recovered phage DNA was processed
as described for the human patient and sequenced using the Illumina HiSeq platform.
Sequence analysis of 25 different tissues recovered over 101 million peptide sequences.
Since this initial animal, we have performed screens in three additional rhesus macaques
with colon adenocarcinoma arising from HNPCC. We plan to compile and crossreference this extensive database of almost half a billion peptide sequences recovered
from phage display screens in humans, non-human primates, pigs, mice, and rats.
Identification of the same tissue specific motifs in multiple species will reinforce their
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specificity, adding great value and confidence for drug-delivery strategies. Likewise,
knowledge of divergent motifs in specific tissues would be of significant value as these
would represent poor candidates for testing in preclinical models.
As the next step in bioinformatics analysis, we plan to continue to develop and
improve our ability to study large-scale datasets. For example, topological data analysis
involves the use of algorithms to uncover qualitative geometric insights from complex
data [89]. For high-throughput phage display applications, these insights would include
defining the multi-dimensional shape and connectedness of clusters containing ligands in
an organ or tissue of interest. A similar analysis has previously been performed using
high-throughput microarray data collected in a cohort of breast cancer patients. By
computationally identifying shape characteristics in the high-dimensional data previously
only defined by tumor or normal samples, investigators were able to distinguish between
several molecular subtypes of disease and define a previously unknown subgroup with
excellent survival [90]. We plan to develop methods to compute the fundamental
geometric properties of our dataset and next apply statistical tools in order to extract
subgroups of clusters that represent novel targeting moieties for tissues of interest. This
complex analysis would allow for the identification of even more robust molecular
targets in disease as well as serve to further our understanding of the vascular map.
Although we have generated an extensive list of organ and tissue specific motifs
and peptides, here, we chose to focus on HCC and introduce a novel tumor targeting
peptide. In cancer therapy, the molecular heterogeneity of the vascular endothelium is an
important determinant for the selective homing of drugs to diseased tissue. The use of
combinatorial phage library selection has previously been highly successful towards
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translational applications to treat or image disease in humans. These strategies are
especially advantageous in diseases with an angiogenic component including HCC
tumors. Identification of vascular markers directly in humans enables confidence in the
translation of targeted delivery strategies to the clinic. Cell surface binding assays as well
as in vitro internalization assays both showed that phage displaying the SGVGAASL
peptide bound and internalized into the HCC cell line, HEPG2, while untargeted control
phage did not. A pilot in vivo experiment in mice bearing orthotopically implanted HCC
tumors showed that SGVGAASL peptide labeled with infrared dye localized to the tumor
site in a dose-dependent manner. These data suggest that peptide SGVGAASL could
potentially be used as a novel probe for the targeting of HCC vascular beds.
Targeting of drugs and imaging agents to both diseased and normal tissues are of
high interest for a plethora of therapeutic strategies including delivery of cytotoxic and
imaging agents as well as gene therapy vectors. We plan to proceed with the conjugation
of SGVGAASL to the pro-apoptotic moiety D[KLAKLAK]2 as a selective therapy in
HCC. Extensive biodistribution, pharmacokinetic, and survival studies will be performed
in preclinical models of HCC established using cell lines both positive (HEP3B and
HEPG2) and negative (SNU449) for SGVGAASL peptide binding and receptor
expression.
Recently, targeted therapy has been explored in the context of tumor
heterogeneity. It is well known that within a cancer type, there exists multiple cell subpopulations arising from a Darwinian clonal evolution driven by genetic instability and
harboring distinct phenotypic alterations [91, 92]. Molecular therapy strategies aiming to
interfere with these specific aberrant mechanisms driving cancer growth and progression
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are challenged by high failure rates due to a lack of systemic specificity or limited
efficacy in only a small number of patients [92]. Predictive biomarkers that aid in the
assignment of targeted therapy in patients who are identified by their molecular profile as
able to benefit represent the next step towards improving their clinical care. In fact, the
FDA has already implemented a “one-arm adaptive trial” for fast tracking the clinical
development of drugs for which a predictive biomarker is already defined as a companion
diagnostic [92].
Here, the purification of the corresponding receptor that serves as the tumorspecific target for SGVGAASL peptide-mediated binding allows for the concurrent
identification of a biomarker that could potentially predict patient response to a drug
targeted by the SGVGAASL peptide. Selective binding of phage displaying the
SGVGAASL peptide to the giantin protein was confirmed using immunocapture binding
assays where nontargeted phage showed very low binding. When the experiment was
repeated using giantin isolated from plasma membrane fractions, phage displaying the
SGVGAASL peptide still bound preferentially to immunocaptured giantin suggesting
that the conformation of the interaction site is not altered based on the cellular
localization of giantin. Preliminary IHC analysis on patient HCC tissue uncovered a
subset of patients that exhibited high expression of giantin on the surface of tumorassociated endothelial cells. We predict that this subgroup of patients would benefit the
most from a therapy targeted through giantin ligand/receptor interaction. Potentially
moving forward with clinical studies, giantin expression could be used to stratify patients
into those predicted to respond to SGVGAASL targeted therapy, supporting the
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qualification for fast track status and greatly reducing the time and costs associated with
clinical trials.
Previously, giantin has been described as a conserved Golgi membrane protein
that may participate in the formation of intercisternal cross-bridges of the Golgi complex
[93]. Structurally, giantin has a single transmembrane domain at the C-terminus that
anchors the protein to the Golgi membrane. The remaining 350 kDa domain is located in
the cytoplasm and forms a rod shaped structure made up of coiled-coiled (heptad) repeats
(estimated to be 1.5 x 250 nm in total size). Giantin behaves similarly to a secretory
protein where, after translation, it inserts into the endoplasmic reticular (ER) membrane,
is incorporated into transport vesicles and retained in the Golgi [94]. The cytoplasmic
domain forms a highly elongated disulfide linked homodimer that serves as the receptor
for the p115 protein and facilitates docking of COPI vesicles (transport cargo from ER to
Golgi and back) to the Golgi membrane [95-97].
In an extensive study of giantin expression in human tissue, strong staining in the
tumor endothelium was observed in a subset of HCC patient samples. Out of 30 samples
obtained from the Surgical Oncology Department at the University of Texas MD
Anderson Cancer Center, 40% exhibited similar endothelial cell surface expression as
observed in patient 6. Commercially obtained HCC samples paired with adjacent normal
liver tissue (N=7) also confirmed this vessel expression pattern as well as an overall
increase in giantin expression in tumor tissue where normal liver tissue showed no
vascular expression. When a TMA containing 142 samples of liver tumor, inflammatory
liver, and normal liver patient tissue was evaluated, giantin expression was positive on
the membrane of tumor vasculature in over 65% of HCC tissues. Early and late stage
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tumors exhibited higher vascular expression of giantin and malignant cell expression of
giantin correlated with higher vascular expression of giantin. When samples positive for
giantin in the vasculature were examined, HCC samples exhibited the strongest staining
when compared to inflammatory liver samples and normal liver samples which never
exhibited more than faint staining in the vasculature. Again, these results confirm in a
large sample size that expression of giantin in the vasculature is increased on the surface
of endothelial cells within the tumor microenvironment. This unique membrane
expression represents an excellent target for tumor specific delivery of imaging and drug
agents.
In a study of five additional cancer types (prostate, breast, colon, lung, and
ovarian cancer), giantin was expressed in higher quantities in malignant tissue from the
prostate, breast, and ovarian malignant tissue compared to benign tissue. However,
significant vascular expression of giantin was not observed in any of the five cancer types
studied. This may be because hepatic sinusoids also referred to as open pore capillaries
are composed of specialized fenestrated endothelium that sometimes has different
staining characteristics compared to endothelium in other tissues [98]. The specialized
nature of the hepatic vessels may explain differences in giantin expression in the small
vessels associated with hepatic malignancies as compared to other types of cancers.
Flow cytometry experiments showed that giantin, the endogenous receptor
mediating SGVGAASL binding, is expressed on the surface of HCC cell lines HEPG2
and HEP3B but not on the surface of SNU449 cells. These findings were confirmed by
examination of giantin expression on plasma membrane protein fractions in these cell
lines. These results correlate with previous findings showing that SGVGAASL peptide
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displaying phage exhibited no preferential specificity to the HCC cell line, SNU449.
These findings are in contrast to immunohistochemical analysis in patient tissues where
giantin expression was not positive on the membrane of malignant cells; however, this
discrepancy may be due to the presence of mosaic tumor vessels in HCC. In fact,
characterization of tumor vasculature in an orthotopic mouse model of HCC established
using the HEP3B cell line revealed that over 60% of vessels present were mosaic (contain
both tumor and endothelial cells making up the luminal surface of the endothelium) [99].
Cell surface expression of giantin was also observed in activated HDMEC
endothelial cells; however, overall expression was quite low compared to HCC cell lines.
It is known that endothelial cell heterogeneity varies significantly between organ systems
and is not easily modeled in in vitro settings [4, 100]. Furthermore, our studies have
shown that the increased expression of giantin on the plasma membrane is only
significantly observed in vessels associated with HCC. Thus, it is unlikely that significant
plasma membrane expression of giantin would be observed in endothelial cells derived
from human skin.
Interestingly, the subcellular localization of giantin has never been described with
respect to the plasma membrane. However, in the literature, there are multiple cases of
proteins exhibiting dual functionality in multiple cellular compartments. An example
from our own group involves work performed by Mintz et al. in 2009 where it was found
that the intracellular protein Crkl is released from tumor cells and binds to β1 integrins on
the cell surface, going on to trigger downstream signaling events [101]. Conditional
localization on the cell surface has been identified for multiple types of intracellular
molecules including proteins involved with stress-response and nuclear proteins
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including transcription factors and DNA repair proteins where translocation usually
occurs in response to environmental stress [23, 25, 102-105]. Functionality on the cell
surface may be distinct from intracellular functions and some have been shown to
promote metastasis and invasion in cancer and represent ideal targets for anti-cancer
therapy [23, 101, 106]. For example, the heat-shock protein GRP78 is part of an
evolutionarily conserved, ER-linked stress response mechanism that provides cellular
survival signals during environmental and physiologic duress including acidosis, hypoxia
and imbalanced glucose metabolism occurring in tumor cells [107, 108]. We, and others,
have previously demonstrated that GRP78 can exist on the surface of breast cancer cells
and that the abundance of cell-surface localized GRP78 increases during metastatic
progression [25, 109, 110]. Fusion of a pro-apoptotic motif to a GRP78 targeting peptide
enabled the induction of cell death in breast cancer metastatic nodules establishing the
usefulness of conditional cell surface proteins for the targeted delivery of cytotoxic drugs
[111].
Aberrant giantin function has also never been linked to involvement in any type
of cancer. However, an examination of normal giantin function uncovered a role for
Golgi dysfunction in several human diseases. Previous work has shown that increased
and dispersed giantin expression occurs during vascular remodeling in both primate
models of pulmonary artery hypertension (PAH) as well as in patients with PAH [112,
113]. A hallmark of PAH is persistent hypoxia where Golgi fragmentation occurs as a
result of the cellular response to stress. In hypoxic pulmonary arterial endothelial cells,
Golgi tether impairment was observed as well as cytoplasmic dispersal and increased
cellular content of the giantin protein leading to a promotion in cell mitosis and
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proliferation [112-114]. Hypoxia is known to promote invasion, metastasis, and drug
resistance in HCC as well as several other types of solid tumors [115-117]. In the future,
we plan to examine the link between increased overall giantin expression during hypoxia
and stress in the context of tumor establishment, progression, and aggressiveness as well
as translocation of giantin to the surface of tumor-associated endothelial cells.
In our studies, shRNA-mediated depletion of giantin in HCC cells led to a
decrease in cell proliferation indicating that giantin function is required for cell survival.
This does not come as a surprise given the pivotal role of giantin in Golgi apparatus
function and cellular trafficking; however, when giantin expression was silenced in HCC
cells, we also found that cells exhibited a loss of adhesion. Cell adhesion dysfunction is a
critical component during cancer invasion and metastasis [118]. Previous work involving
siRNA-mediated depletion of giantin has been performed in the HeLa cell line where
knockdown of giantin expression resulted in alterations in glycosylation of cell surface
proteins [119]. Interestingly, in this study, no changes in cell proliferation or adhesion
were observed suggesting a unique role for giantin in HCC.
In addition to links to hypoxia and giantin function, antibodies against giantin
have been found in the circulation of patients with autoimmune disorders including lupus
erythematosus and Sjögren's syndrome as well as those positive for human
immunodeficiency virus [120, 121]. Furthermore, anti-giantin positive sera exhibit low
titer for antibodies recognizing epitopes in the C-terminal transmembrane domain of
giantin and high titer with strong reactivity for antibodies recognizing the N-terminal and
central domains that are located on the cytoplasmic extension of giantin anchored in the
Golgi membrane [120]. Further analysis of the SGVGAASL peptide binding site will
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focus on localizing the binding affinity to the C- or N-terminal domain of giantin. Most
likely, we will observe similar binding affinities as circulating autoantibodies against
giantin indicating a similar mechanism for exposure of the protein to the extracellular
environment through its transmembrane domain.
During apoptosis, giantin rapidly undergoes site specific caspase-3 mediated
cleavage at a conserved site shutting down vesicular trafficking between the ER and
Golgi apparatus [122]. One group hypothesizes that when cells undergo unregulated cell
death including apoptosis or necrosis resulting from injury, infection, or failure to clear
dying cells, the giantin protein may be recognized as a cell surface structure [120].
Combined with the findings of giantin function in hypoxic and apoptotic cells, a
tantalizing role for this protein in inflammation arises. In many cancers, inflammation
plays an important role in cancer growth and progression [123]. In particular, the
hallmark risk factor for HCC is cirrhosis and chronic liver disease which involves each of
the disease states described above: inflammation, cell death and hypoxia collectively
resulting in promotion of angiogenesis and tumor initiation [124]. We have shown that
faint expression of giantin in the vasculature was observed in all samples of inflammatory
liver including viral hepatitis related cirrhosis and fatty liver (steatosis). In the future, we
plan to examine giantin expression and cellular localization in a premalignant setting
perhaps identifying a role for giantin as a marker for HCC risk.
An additional translational path of study we will focus on involves the integration
of the SGVGAASL peptide into a multi-functional hybrid vector incorporating adenoassociated virus (AAV) genomic elements and M13-derived phage [125]. This ligandtargeted, AAV/phage (AAVP) chimera displaying a tumor specific peptide will mediate
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selective internalization of the viral particles through specific ligand-receptor interactions
as well as facilitate the delivery of reporter genes that can be used for imaging, diagnosis
and treatment of disease. If a link to giantin expression and premalignancy is uncovered,
this type of delivery strategy would serve as an excellent modality for disease detection
and identifying patients at risk of developing HCC. Furthermore, towards developing a
therapy against HCC, this platform also allows for reporter gene control at the
transcriptional level through insertion of promoters active in cells of interest. Although
our giantin binding peptide may bind at different levels to both inflammatory liver
vasculature as well as tumor vasculature, integration of a tumor specific promoter or
inflammatory liver specific promoter to drive transgene expression would allow for
selective expression of the transgene only in cells of interest. Moving forward, we have
plans to thoroughly explore the activity of HCC targeted AAVP constructs in multiple
models of liver disease and liver tumors so as to realize its clinical potential.
In conclusion, the examination of high-throughput data sets recovered from phage
screenings directly in a patient offers a plethora of opportunities for uncovering novel
protein interactions in the vasculature of normal and disease tissue. Many of these
interactions can be exploited for drug delivery or imaging purposes as well as examined
for roles in disease persistence and progression. As our understanding of the vascular
landscape expands, functional discovery of complex protein networks involved in normal
and disease functions combined with accumulating genomic knowledge has the potential
to make a significant impact in our understanding of disease mechanisms as well as
innovations in clinical care.
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